Updated on 2025/08/01

All information, except for affiliations, is reprinted from the information registered on researchmap.

写真a

 
Masaharu Hata
 
Organization
Graduate School of Medicine Department of Medicine Radiology Professor
School of Medicine Medical Course
Title
Professor
Profile
日本医学放射線学会の放射線治療専門医および研修指導者で、日本がん治療認定医指導責任者。頭頸部がん、肺がん、肝臓がん、膀胱がんなどの粒子線治療の研究成果を発表。また、子宮頸がん、皮膚がん、悪性リンパ腫などの新規治療法に関する研究発表を行い、米国放射線腫瘍学会(ASTRO)で受賞。日本医学放射線学会、日本放射線腫瘍学会代議員。

横浜市立大学放射線医学
http://www-user.yokohama-cu.ac.jp/~radiolog/
External link

Degree

  • 博士(医学) ( 横浜市立大学 )

Research Interests

  • Radiation Therapy

  • Particle Therapy

  • Stereotactic Radiosurgery

  • High-Precision Radiation Therapy

  • 放射線腫瘍学

  • 放射線治療

  • Particle-beam radiation therapy

  • 小線源治療

  • 強度変調放射線治療

  • Brachytherapy

  • Intensity-Modulated Radiation Therapy

  • Stereotactic Radiation Therapy

  • Stereotactic irradiation

  • 高精度放射線治療

  • Radiation Oncology

Research Areas

  • Life Science / Radiological sciences  / Radiation oncology

Research History

  • Yokohama City University   Graduate School of Medicine, Graduate   Professor

      More details

Committee Memberships

  • 日本放射線腫瘍学会   代議員  

       

      More details

    Committee type:Academic society

    researchmap

  • 日本医学放射線学会関東地方会   世話人  

       

      More details

    Committee type:Academic society

    researchmap

  • 日本医学放射線学会   代議員  

       

      More details

    Committee type:Academic society

    researchmap

  • Journal of Oncology and Cancer Research.   Editor.  

       

      More details

    Committee type:Academic society

    researchmap

  • 横浜放射線医会   理事  

       

      More details

    Committee type:Academic society

    researchmap

  • Annals of Radiation Therapy and Oncology.   Editor.  

       

      More details

    Committee type:Academic society

    researchmap

  • Journal of Cancer and Tumor International.   Editor.  

       

      More details

    Committee type:Academic society

    researchmap

  • Japanese Journal of Radiology.   Editor.  

       

      More details

  • Journal of Radiation Research.   Editor.  

       

      More details

    Committee type:Academic society

    researchmap

  • 横浜放射線治療懇話会   代表世話人  

       

      More details

    Committee type:Academic society

    researchmap

  • 神奈川県放射線医会   理事  

       

      More details

    Committee type:Academic society

    researchmap

▼display all

Papers

  • Long-term outcomes of salvage radiotherapy using TomoTherapy with image-guided radiotherapy for postoperative prostate cancer patients. Reviewed

    Mukai Y, Omura M, Minagawa Y, Mase M, Nishikawa Y, Miura I, Hata M

    Cancer Diagnosis and Prognosis   5 ( 2 )   189 - 197   2025.3

     More details

  • Infectious complications in patients receiving superselective intra-arterial chemoradiotherapy for oral squamous cell carcinoma. Reviewed

    Kato H, Ohya T, Koizumi T, Iida M, Takano S, Hata M, Nakajima H, Mitsudo K

    Oral Diseases   in press   2025

     More details

  • Relationship between dose and local control in five-fraction stereotactic body radiotherapy for hepatocellular carcinoma. Reviewed

    Nishikawa Y, Ogino I, Mukai Y, Funaoka A, Takeda Y, Hata M

    In Vivo   in press   2025

     More details

  • Unexpected change in hydrogel spacer volume during external-beam radiation therapy. Reviewed

    Ishibashi N, Hata M, Fujikawa A, Mochizuki T, Maebayashi T, Okada M

    Japanese Journal of Radiology   42 ( 11 )   1315 - 1321   2024.11

     More details

  • Identification of factors contributing to testosterone recovery after hormone therapy combined with external radiation therapy for localized prostate cancer. Reviewed

    Yokomizo Y, Itoh Y, Kawahara T, Hayashi N, Miyoshi Y, Makiyama K, Hata M, Uemura H

    In Vivo   38 ( 4 )   2074 - 2079   2024.7

     More details

  • Patterns and incidence of pneumonitis and initial treatment outcomes with durvalumab consolidation therapy after radical chemoradiotherapy for stage III non-small cell lung cancer. Reviewed

    Sato M, Odagiri K, Tabuchi Y, Okamoto H, Shimokawa T, Nakamura Y, Hata M

    Cancers   16 ( 6 )   1162   2024.3

     More details

  • A unique adverse event of radiotherapy in a patient with IgG4-related disease: a case report. Reviewed

    Aimi H, Murai T, Takino K, Naito W, Miura I, Hata M, Inoue T, Omura M

    In Vivo   37 ( 6 )   2840 - 2844   2023.11

     More details

  • Toxic effects of esophageal squamous cell cancer treated with volume modulated arc therapy: preliminary clinical results. Reviewed International journal

    Shigenaga D, Ogino I, Watanabe N, Hata M

    Anticancer Research : the International Institute of Anticancer Research / IIAR   43 ( 6 )   2791 - 2798   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: To evaluate the toxic effects associated with various factors, including the presence or absence of concurrent chemotherapy with volume-modulated arc therapy (VMAT) and dose parameters for esophageal cancer (EC), and to assess the safety and feasibility of the VMAT protocol. PATIENTS AND METHODS: Patients with EC who received definitive VMAT between December 2016 and December 2020 were retrospectively analyzed. VMAT plans were designed to deliver 60 Gy to the primary tumor, 54 Gy to high-risk sites, and 51.3 Gy to regional lymph node sites. Toxic effects were evaluated for esophagitis, neutropenia, esophageal stricture, pericardial effusion, radiation-associated pneumonia. RESULTS: Forty-five patients received concurrent chemoradiotherapy (CCRT), while 29 were treated with radiation therapy (RT) alone. The following grade 3 complications were detected: Neutropenia in four patients (5.4%), esophagitis in two (2.7%), and esophageal stricture in one (1.4%). Grade 4 or more complications were not observed. The median age of the CCRT group (67 years) was significantly lower than that of the RT-alone group (77 years) (p<0.0001). The incidence of esophagitis was significantly higher in the CCRT group (75.5%) than in the RT group (48.3%) (p=0.033). The univariate analysis identified increasing mean dose to the pericardium as a significant risk factor for pericardial effusion, and CCRT and performance status ≥1 as significant for radiation-associated pneumonia. These factors were not significant in the multivariate analysis. Neutropenia and esophageal stricture were not associated with any factor examined. CONCLUSION: VMAT alone and in CCRT performed with our protocol was safe and feasible in patients with esophageal squamous cell cancer.

    DOI: 10.21873/anticanres.16448

    PubMed

    researchmap

  • Long-term outcomes of early-stage non-stomach gastrointestinal MALT lymphoma treated with radiation therapy. Reviewed International journal

    Ito E, Sugiura M, Watanabe N, Tayama Y, Takano S, Ogino I, Hata M

    Anticancer Research : the International Institute of Anticancer Research / IIAR   43 ( 6 )   2851 - 2857   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Non-stomach gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma is rare, and there are only a few reports regarding radiation therapy (RT) for non-stomach gastrointestinal MALT lymphoma. There has been no established cure and no reports on RT use with long-term follow-up. Herein, we report a retrospective long-term investigation of early-stage non-stomach gastrointestinal MALT lymphoma. Our aim was to evaluate whether RT is a valid treatment option for this disease. PATIENTS AND METHODS: We retrospectively analyzed 6 patients who were diagnosed with early-stage non-stomach gastrointestinal MALT lymphoma and received RT. The median age was 66 years (range=38-89 years). The primary tumor originated from the duodenum in 2 patients and from the rectum in 4 patients. The RT dose was 30-34 Gy in 15-20 fractions to the involved site or field, depending on the case. RESULTS: The median follow-up time was 89.5 months (range=6-170). All patients had complete remission within 3 months after RT. The 5-year overall survival and progression-free survival rates were 83.3% and 100%, respectively. During the observation period, no patient had a confirmed recurrence. One patient died of causes unrelated to cancer or treatment. There were no late toxicities by RT. CONCLUSION: Our results show good long-term local control and no late toxicities requiring treatment. Moderate-dose RT was appropriate and well tolerated for early-stage non-stomach gastrointestinal MALT lymphoma.

    DOI: 10.21873/anticanres.16454

    PubMed

    researchmap

  • Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas. Reviewed

    Chen X, Kioi M, Hayashi Y, Koizumi T, Koike I, Yamanaka S, Hata M, Mitsudo K

    Radiation Oncology (London, England)   18 ( 1 )   90   2023.5

     More details

  • Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer. Reviewed

    Yabushita Y, Matsuyama R, Miyake K, Homma Y, Kumamoto T, Misumi T, Hata M, Yamanaka S, Fujii S, Endo I

    Journal of Hepato-Biliary-Pancreatic Sciences   30 ( 4 )   493 - 502   2023.4

     More details

  • Prognostic markers including immune and inflammatory factors predict outcomes in patients receiving postoperative radiation therapy for cholangiocarcinoma. Reviewed International journal

    Mukai Y, Matsuyama R, Sugiura M, Yabushita Y, Taniuchi R, Homma Y, Hashimoto K, Miyake K, Tabuchi Y, Endo I, Hata M

    Asia-Pacific Journal of Clinical Oncology : an official journal of the Chinese Society of Clinical Oncology (CSCO), Clinical Oncology Society of Australia (COSA), Korean Association for Clinical Oncology (KACO), Medical Oncology Group of Australia (MOGA)   19 ( 1 )   226 - 233   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: This study aimed to analyze treatment outcomes and prognostic markers, including immune and inflammatory factors, of postoperative radiation therapy (RT) administered to patients with cholangiocarcinoma (CCA). METHODS: We retrospectively included 59 patients with CCA who underwent surgery and postoperative RT with curative intent from 2004 to 2019. Patients received external irradiation (50 Gy in 25 fractions) using three-dimensional RT. We analyzed prognostic factors of inflammation, such as pre-RT platelet count, hemoglobin, lymphocyte count ratio (LCR) of the leukocyte count, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR). RESULTS: Tumor stages were distributed as follows: I (n = 8), II (n = 25), III (n = 15), and IVA (n = 11). The median follow-up was 24 months. Two-year overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and locoregional control (LRC) rates were 59.5%, 62.0%, 40.1%, and 66.7%, respectively. Univariate analysis revealed that lower LCR was significantly associated with shorter PFS (p = 0.0446). There was no significant difference between the median baseline values of PLR and NLR; and age ≥75, positive regional lymph node metastases (N+), and chemotherapy after RT were significantly associated with poor OS. Multivariate analysis revealed a significant association of N+ with worse OS, PFS, and CSS and that lower LCR was significantly associated with better PFS (p = 0.0234). Among late toxicity events, two patients (3.38%) were suspected with therapy-related liver toxicity. CONCLUSIONS: Lower LCR before RT was a better prognostic factor for postoperative RT of patients with CCA.

    DOI: 10.1111/ajco.13809

    PubMed

    researchmap

  • Radiation therapy for pelvic recurrent colorectal or gynecological cancer: is whole pelvic irradiation necessary? Reviewed International journal

    Ishibashi N, Maebayashi T, Hata M, Aizawa T, Sakaguchi M, Okada M

    Annals of Palliative Medicine : an official journal of the Society for Palliative Radiation Oncology   11 ( 6 )   1855 - 1864   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Preoperative whole pelvic radiation therapy (RT) is used commonly for rectal cancer and is the standard field postoperatively in gynecological cancer. However, the ideal field (local vs. whole pelvis) has not been determined for local recurrence of these cancers. METHODS: We retrospectively reviewed the data for 52 patients who developed local tumor recurrence of rectal or gynecological cancer treated from 2013 to 2021. The initial treatment for all patients was total excision of the primary tumors without radiation therapy. Radiation therapy targets were surgical stumps, perianastomosis sites, and pelvic lymph nodes, classified according to the pelvic nodal volume atlas for radiation therapy. Patients were divided into the local recurrent tumor only radiation therapy group and the whole pelvis radiation therapy group. Whole pelvis radiation therapy included the common iliac lymph nodes or prophylactic lymph nodes below the L5/S1 junction. We recorded second recurrence after RT and the affected site(s) in each group. We also compared disease-specific survival using uni- and multivariate analyses. RESULTS: We found no significant differences between the groups regarding second recurrence or regarding the site(s) of recurrence. We also found no significant differences in disease-specific survival between the two RT groups. However, patients who did not receive chemotherapy after the initial surgery and before RT had significantly longer survival (P=0.015). CONCLUSIONS: In patients with locally recurrent rectal or gynecological cancer, we found no significant difference in second recurrence or survival between the local tumor only RT field and the whole pelvic RT field.

    DOI: 10.21037/apm-21-2950

    PubMed

    researchmap

  • Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. Reviewed

    Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, Kobayashi N, Utsunomiya D, Hata M, Ichikawa Y, Tanabe M, Hosono M, Kinuya S

    Journal of Hepato-Biliary-Pancreatic Sciences   29 ( 4 )   487 - 499   2022.4

     More details

  • Sequential chemotherapy after definitive radiotherapy in markedly elderly patients with advanced esophageal cancer. Reviewed

    Watanabe S, Ogino I, Kunisaki C, Hata M

    Indian Journal of Cancer : an official journal of the Indian Cancer Society   59 ( 2 )   244 - 250   2022.4

     More details

  • Impact of regional lymph node irradiation on reducing lymph node recurrence in esophageal cancer patients. Reviewed

    Watanabe S, Ogino I, Shigenaga D, Hata M

    Cancer Diagnosis & Prognosis   2 ( 2 )   223 - 231   2022.3

     More details

  • Dose to contralateral breast from whole breast irradiation by automated tangential IMRT planning: comparison of flattening-filter and flattening-filter-free modes. Reviewed

    Ogino I, Seto H, Shigenaga D, Hata M

    Reports of Practical Oncology and Radiotherapy   27 ( 1 )   113 - 120   2022.3

     More details

  • Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Reviewed

    Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Kaneta T, Utsunomiya D, Hata M, Inoue T, Hosono M, Kinuya S, Ichikawa Y

    Annals of Nuclear Medicine   35 ( 12 )   1332 - 1341   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression. We have, for the first time, reported the results of the tolerability, safety, pharmacokinetics, dosimetry, and efficacy of this treatment for Japanese patients with NET. METHODS: Patients with unresectable, somatostatin receptor scintigraphy (SRS)-positive NETs were enrolled in this phase I clinical trial. They were treated with 29.6 GBq of 177Lu-DOTATATE (four doses of 7.4 GBq) combined with amino acid solution infusion plus octreotide long-acting release (LAR) 30 mg. The primary objective of this study was to evaluate the tolerability, safety, pharmacokinetics, and dosimetry of a single administration of this treatment in patients with SRS-positive NETs. RESULTS: Six Japanese patients (three men and three women; mean age 61.5 years; range 50-70 years) with SRS-positive unresectable NETs were recruited. 177Lu-DOTATATE was eliminated from the blood in a two-phase manner. Cumulative urinary excretion of radioactivity was 60.1% (range 49.0%-69.8%) within the initial 6 h. The cumulative renal absorbed dose for 29.6 GBq of 177Lu-DOTATATE was 16.8 Gy (range 12.0-21.2 Gy), and the biological effective dose was 17.0 Gy (range 12.2-21.5 Gy). Administration of 177Lu-DOTATATE was well tolerated, with no dose-limiting toxicities. Grade 3 lymphopenia occurred in two (33.3%) cases, but there were no other severe toxicities. Four patients achieved partial response (objective response rate, 66.7%), one patient had stable disease, and one patient had progressive disease. CONCLUSION: PRRT with 177Lu-DOTATATE was well-tolerated and showed good outcomes in Japanese patients with unresectable NETs. Peptide receptor radionuclide therapy, 177Lu-DOTA0-Tyr3-octreotate .

    DOI: 10.1007/s12149-021-01674-9

    PubMed

    researchmap

  • Relationship between radiation pneumonitis following definitive radiotherapy for non-small cell lung cancer and isodose line. Reviewed

    Watanabe S, Ogino I, Shigenaga D, Hata M

    In Vivo   35 ( 6 )   3441 - 3448   2021.11

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Anticancer Research USA Inc.  

    DOI: 10.21873/invivo.12644

    researchmap

  • Whole-brain radiation therapy for intracranial metastases as initial or late treatment. Reviewed

    Hiranuma H, Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Hata M, Okada M, Gon Y

    In Vivo   35 ( 4 )   2445 - 2450   2021.7

     More details

  • Outcome of radiation therapy for stage IVB uterine cervical cancer with distant lymph nodes metastases; sequential irradiation for distant lymph nodes metastases. Reviewed International journal

    Mukai Y, Yokota NR, Sugiura M, Mizushima T, Taniuchi R, Imai Y, Hashimoto K, Tabuchi Y, Miyagi E, Hata M

    In Vivo   35 ( 2 )   1169 - 1176   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: This study aimed to evaluate the outcome of radiation therapy for patients with distant lymph node (LN) metastases, without organ metastases from uterine cervical cancer (UCC). PATIENTS AND METHODS: Twenty-six patients with UCC with distant LN metastases received radiotherapy and were retrospectively analyzed. The sites of distant LN metastasis were as follows; Supraclavicular in 19, inguinal in nine, axillary in four, and others in three. The mean dose prescribed for these was 50 (range=40-60) Gy. RESULTS: The 2-year overall, cause-specific, and progression-free survival, and local control of primary tumor rates were 51.3%, 51.3%, 46.9%, and 67.9%. In multivariate analysis, performance status ≥1 (p=0.007), para-aortic LN metastases (p=0.001), and lack of high-dose-rate intracavitary brachytherapy (p=0.033) were significantly associated with poor overall survival. Performance status ≥1 (p=0.004), and para-aortic LN metastases (p=0.014) were significantly associated with poor cause-specific survival. CONCLUSION: This study demonstrated favorable local control in patients with UCC with distant LN metastases.

    DOI: 10.21873/invivo.12365

    PubMed

    researchmap

  • Proton beam therapy for a giant hepatic hemangioma: a case report and literature review. Reviewed

    Shimizu S, Mizumoto M, Okumura T, Li Y, Baba K, Murakami M, Ishida T, Nakamura M, Hiroshima Y, Iizumi T, Saito T, Numajiri H, Nakai K, Hata M, Sakurai H

    Clinical and Translational Radiation Oncology   3 ( 27 )   152 - 156   2021.2

     More details

  • Radiotherapy for non-gastric intestinal versus gastric MALT lymphoma: a comparison of treatment outcomes. Reviewed

    Watanabe S, Ogino I, Hata M

    Blood Research : an official journal of the Korean Society of Hematology   55 ( 4 )   200 - 205   2020.12

     More details

  • Impact of superselective intra-arterial and systemic chemoradiotherapy for gingival carcinoma; analysis of treatment outcomes and prognostic factors. Reviewed International journal

    Mukai Y, Hayashi Y, Koike I, Koizumi T, Sugiura M, Oguri S, Takano S, Kioi M, Sato M, Mitsudo K, Hata M

    BMC Cancer   20 ( 1 )   1154 - 1154   2020.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: We compared outcomes and toxicities between concurrent retrograde super-selective intra-arterial chemoradiotherapy (IACRT) and concurrent systemic chemoradiotherapy (SCRT) for gingival carcinoma (GC). METHODS: We included 84 consecutive patients who were treated for non-metastatic GC ≥ stage III, from 2006 to 2018, in this retrospective analysis (IACRT group: n = 66; SCRT group: n = 18). RESULTS: The median follow-up time was 24 (range: 1-124) months. The median prescribed dose was 60 (6-70.2) Gy (IACRT: 60 Gy; SCRT: 69 Gy). There were significant differences between the two groups in terms of 3-year overall survival (OS; IACRT: 78.8, 95% confidence interval [CI]: 66.0-87.6; SCRT: 50.4, 95% CI: 27.6-73.0; P = 0.039), progression-free survival (PFS; IACRT: 75.6, 95% CI: 62.7-85.2; SCRT: 42.0, 95% CI: 17.7-70.9; P = 0.028) and local control rates (LC; IACRT: 77.2, 95% CI: 64.2-86.4; SCRT: 42.0, 95% CI: 17.7-70.9; P = 0.015). In univariate analysis, age ≥ 65 years, decreased performance status (PS) and SCRT were significantly associated with worse outcomes (P < 0.05). In multivariate analysis, age ≥ 65 years, clinical stage IV, and SCRT were significantly correlated with a poor OS rate (P < 0.05). Patients with poorer PS had a significantly worse PFS rate. Regarding acute toxicity, 22 IACRT patients had grade 4 lymphopenia, and osteoradionecrosis was the most common late toxicity in both groups. CONCLUSIONS: This is the first report to compare outcomes from IACRT and SCRT among patients with GC. ALL therapy related toxicities were manageable. IACRT is an effective and safe treatment for GC.

    DOI: 10.1186/s12885-020-07638-y

    PubMed

    researchmap

  • Treatment outcome of the combination therapy of high-dose rate intracavitary brachytherapy and intensity-modulated radiation therapy with central-shielding for cervical cancer. Reviewed

    Mukai Y, Minagawa Y, Inoue H, Sato A, Matsui K, Fukuda T, Onuma K, Hongo H, Shirata R, Nagata H, Hashimoto H, Inoue T, Hata M, Omura M

    In Vivo   34 ( 6 )   3387 - 3398   2020.11

     More details

  • Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. Reviewed

    Hayashi N, Osaka K, Muraoka K, Hasumi H, Makiyama K, Kondo K, Nakaigawa N, Yao M, Mukai Y, Sugiura M, Takano S, Ito E, Kaizu H, Koike I, Hata M, Taguri M, Miyoshi Y, Izumi K, Kawahara T, Uemura H

    World Journal of Urology : an official journal of the Société Internationale d'Urologie   38 ( 10 )   2477 - 2484   2020.10

     More details

  • The role of palliative radiation therapy in treating pleural or peritoneal disseminated tumors: 22 cases and a review of the literature. Reviewed International journal

    Ishibashi N, Maebayashi T, Hata M, Okada M

    Annals of Palliative Medicine : an official journal of the Society for Palliative Radiation Oncology (SPRO)   9 ( 5 )   2586 - 2591   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Local radiation therapy (RT) can provide pain relief and reduce bleeding resulting from pleural or peritoneal dissemination of primary tumors. However, the optimal RT exposure dose for such tumors is unclear and the response rate is unknown. In this study, we examined the effectiveness of palliative RT for pleural or peritoneal disseminated tumors to determine the optimal dose in these patients. METHODS: The data of 22 patients with pleural- or peritoneal-disseminated tumors who were treated with local RT at our institution between 2011 and 2019 were retrospectively reviewed. RESULTS: Among these patients, 9 (40.9%) had pleural tumors, 13 (59.1%) had peritoneal tumors and 2 had tumors in the peritoneum and umbilicus. The most common primary tumors were lung (22.8%) and pancreatic cancer (18.2%). RT was mainly administered for pain alleviation (72.7%). Three patients (13.6%) received RT for hemostasis. Thirteen patients (59.1%) received a regimen of 30 Gy/10 fractions (fr), with the total dosage for all patients ranging from 27 to 56 Gy. No grade 2 or higher RT-related adverse events occurred. Three and four patients obtained complete and partial responses, respectively. The timing of the measurement of response to pain relief ranged from 0 to 232 (median, 21) days upon completion of RT. Overall response to pain relief occurred in nine of 16 patients (56.3%) with pain before RT. Hemostasis was confirmed in 2 of the 3 patients (66.7%) with bleeding before RT. Twelve of 20 (60%) patients with symptoms before RT responded to RT. Disease-specific survival (DSS) time after RT ranged from 1 to 656 (median, 106) days. CONCLUSIONS: Prompt palliative administration of RT to patients with advanced disease to alleviate pain from disseminated tumors may achieve therapeutic efficacy.

    DOI: 10.21037/apm-19-495

    PubMed

    researchmap

  • Intensity-modulated radiation therapy for lymph node oligo-recurrence. Reviewed

    Sato A, Omura M, Minagawa Y, Matsui K, Shirata R, Hongo H, Hashimoto H, Misumi T, Inoue T, Hata M

    In Vivo   34 ( 5 )   2587 - 2593   2020.9

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Anticancer Research USA Inc.  

    DOI: 10.21873/invivo.12076

    researchmap

  • Partial chest wall radiation therapy for positive or close surgical margins after modified radical mastectomy for breast cancer without lymph node metastasis. Reviewed

    Ishibashi N, Nishimaki H, Maebayashi T, Adachi K, Sakurai K, Masuda S, Hata M, Okada M

    Asia-Pacific Journal of Clinical Oncology : an official journal of the Chinese Society of Clinical Oncology (CSCO), Clinical Oncology Society of Australia (COSA), Korean Association for Clinical Oncology (KACO), Medical Oncology Group of Australia (MOGA)   16 ( 1 )   28 - 33   2020.2

     More details

  • Outcome of radiation therapy for locally advanced vulvar carcinoma: analysis of inguinal lymph node. Reviewed

    Mukai Y, Koike I, Matsunaga T, Yokota NR, Kaizu H, Takano S, Ito E, Sugiura M, Miyagi E, Hata M

    In Vivo   34 ( 1 )   307 - 313   2020.1

     More details

  • National survey on total-body irradiation prior to reduced-intensity stem cell transplantation in Japan: the Japanese Radiation Oncology Study Group. Reviewed

    Kawaguchi H, Soejima T, Ishibashi N, Akiba T, Hasegawa M, Isobe K, Ito H, Imai M, Ejima Y, Hata M, Sasai K, Shimoda E, Oguchi M, Akimoto T, Japanese Radiation Oncology, Study Group

    Journal of Radiation Research   60 ( 5 )   579 - 585   2019.10

     More details

  • Intensity-modulated radiation therapy using TomoDirect for postoperative radiation of left-sided breast cancer including lymph node area: comparison with TomoHelical and three-dimensional conformal radiation therapy. Reviewed

    Takano S, Omura M, Suzuki R, Tayama Y, Matsui K, Hashimoto H, Hongo H, Nagata H, Tanaka K, Hata M, Inoue T

    Journal of Radiation Research   60 ( 5 )   694 - 704   2019.10

     More details

  • Radiation therapy for uterine cervical cancer with lung metastases including oligometastases. Reviewed

    Mukai Y, Koike I, Matsunaga T, Yokota NR, Takano S, Sugiura M, Sato M, Miyagi E, Hata M

    In Vivo   33 ( 5 )   1677 - 1684   2019.9

     More details

  • Lymph Node Metastases Diagnosed by 18F-FDG-PET/CT in Esophageal Squamous Cell Cancer Treated With Concurrent Chemoradiotherapy. Reviewed International journal

    Ichiro Ogino, Shigenobu Watanabe, Toshihiro Misumi, Masaharu Hata, Chikara Kunisaki

    Anticancer Research : the International Institute of Anticancer Research / IIAR   39 ( 9 )   4977 - 4985   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: To evaluate whether factors related to the clinical staging of lymph node (LN) metastasis diagnosed by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (PET/CT) correspond to poor survival in esophageal squamous cell cancer (ESCC) patients treated with concurrent chemoradiotherapy (CCRT). PATIENTS AND METHODS: A total of 69 patients with curative intent and no prior treatment for ESCC or simultaneous treatment for synchronous cancers were investigated. A maximum standardized uptake value (SUVmax) on the highest image pixel in the LN ≥2.5 was considered positive. Location of the involved LN and its impact on survival were analyzed. RESULTS: In the univariate analysis of location, metastasis of the abdominal site, regional abdominal LN, and left gastric LN station negatively affected overall survival (OS) and disease-free survival (DFS). Other adverse clinical factors influencing OS included T4, clinical stage IVA and body mass index <21.2. In terms of DFS, a further unfavorable factor was primary tumor SUVmax ≥10.4. Abdominal site LN metastasis affected both OS and DFS in multivariate analysis. CONCLUSION: LN metastasis diagnosed by PET/CT in abdominal sites was an independent predictor affecting both OS and DFS in ESCC patients who underwent curative CCRT.

    DOI: 10.21873/anticanres.13687

    PubMed

    researchmap

  • Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver. Reviewed International journal

    Mukai Y, Matsuyama R, Koike I, Kumamoto T, Kaizu H, Homma Y, Takano S, Sawada Y, Sugiura M, Yabushita Y, Ito E, Sato M, Endo I, Hata M

    Medicine   98 ( 31 )   e16673   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The aim of this study was to analyze dose-volume histogram (DVH) of the remnant liver for postoperative cholangiocarcinoma (CCA) patients, to find toxicity rates, and to confirm efficacy of postoperative radiation therapy (RT).Thirty-two postoperative CCA patients received partial liver resection and postoperative RT with curative intent. The "liver reduction rate" was calculated by contouring liver volume at computed tomography (CT) just before the surgery and at CT for planning the RT. To evaluate late toxicity, the radiation-induced hepatic toxicity (RIHT) was determined by the common terminology criteria for adverse events toxicity grade of bilirubin, aspartate transaminase, alanine transaminase, alkaline phosphatase, and albumin, and was defined from 3 months after RT until liver metastasis was revealed. The radiation-induced liver disease (RILD) was also evaluated.Tumor stages were distributed as follows: I: 1, II: 8, IIIA: 1, IIIB: 6, IIIC: 14, IVA: 2. Median prescribed total dose was 50 Gy. Median follow-up time was 27 months. Two-year overall survival (OS): 72.4%, disease-free survival: 47.7%, local control: 65.3%, and the median survival time was 40 months. The median "liver reduction rate" was 21%. The OS had statistically significant difference in nodal status (P = .032) and "liver reduction rate" >30% (P = .016). In the association between the ≥grade 2 RIHT and DVH, there were significantly differences in V30 and V40 (P = .041, P = .034), respectively. The grade ≥2 RIHT rates differ also significantly by sex (P = .008). Two patients (6.2%) were suspected of RILD.We suggest that RT for remnant liver should be considered the liver V30, V40 to prevent radiation-induced liver dysfunction.

    DOI: 10.1097/MD.0000000000016673

    PubMed

    researchmap

  • Relationship between nutritional status and esophageal fistula formation after radiotherapy for esophageal cancer. Reviewed

    Watanabe S, Ogino I, Kunisaki C, Hata M

    Cancer Radiothérapie : an official journal of the Société Française de Radiothérapie Oncologique   23 ( 3 )   222 - 227   2019.6

     More details

  • Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy. Reviewed International journal

    Hayashi Y, Osawa K, Nakakaji R, Minamiyama S, Ohashi N, Ohya T, Iida M, Iwai T, Ozawa T, Oguri S, Koizumi T, Hirota M, Kioi M, Hata M, Mitsudo K

    Head & neck   41 ( 6 )   1777 - 1784   2019.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The aim of this study was to evaluate the prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma (SCC) treated with intra-arterial infusion chemotherapy concurrent with radiotherapy. METHODS: A total of 46 patients were reviewed retrospectively in this study. The treatment schedule comprised intra-arterial chemotherapy (total, 60 mg/m2 docetaxel and 150 mg/m2 cisplatin) and three-dimensional computed tomography based, daily conventional radiotherapy (total, 60 Gy/30 fr) for 6 weeks. RESULTS: The median follow-up period was 40 months (range, 3-110 months). The 3-year overall survival and locoregional control rates for all patients were 64.3% and 84.3%, respectively. The OS rate of the patients with N0-1 was significantly higher than that of the patients with N ≥ 2 (P < .05). No grade 5 toxicities were observed. CONCLUSIONS: Intra-arterial infusion chemotherapy concurrent with radiotherapy was effective for advanced maxillary gingival SCC.

    DOI: 10.1002/hed.25607

    PubMed

    researchmap

  • Myelosuppression after radiation therapy in patients with or without autologous peripheral blood stem cell transplantation: a retrospective observation study. Reviewed

    Ishibashi N, Maebayashi T, Sakaguchi M, Aizawa T, Uchino Y, Hata M, Okada M

    Anticancer Research : the International Institute of Anticancer Research / IIAR   39 ( 4 )   2163 - 2167   2019.4

     More details

  • Radiation therapy for elderly patients with uterine cervical cancer: feasibility of curative treatment. Reviewed

    Hata M

    International Journal of Gynecological Cancer : an official journal of the International Gynecologic Cancer Society (IGCS) and the European Society of Gynaecological Oncology (ESGO)   29 ( 3 )   622 - 629   2019.3

     More details

  • Thermochemoradiotherapy using superselective intra-arterial infusion for patients with oral cancer with cervical lymph node metastases. Reviewed International journal

    Nozato T, Koizumi T, Hayashi Y, Iida M, Iwai T, Oguri S, Hirota M, Kioi M, Koike I, Hata M, Tohnai I, Mitsudo K

    Anticancer research : the International Institute of Anticancer Research / IIAR   39 ( 3 )   1365 - 1373   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: We aimed to retrospectively investigate the outcomes and pathological effects of retrograde superselective intra-arterial chemoradiotherapy (IACRT) combined with hyperthermia on metastatic lymph nodes of patients with oral squamous cell carcinoma. PATIENTS AND METHODS: Patients with lymph node metastasis from oral cancer were treated with IACRT using cisplatin plus docetaxel combined with hyperthermia prior to surgical removal 8 weeks after completion of IACRT and hyperthermia. The locoregional control and overall survival rates were calculated using the Kaplan-Meier method. RESULTS: A total of 35 patients received the combination therapy of whom 26 received it as definitive treatment and in the rest, it was administered as preoperative treatment. The 5-year locoregional control and overall survivaI rates were 95.6% and 80.2% in the definitive-treatment group, and 100% and 66.6% in the preoperative-treatment group, respectively. CONCLUSION: The combination therapy provided good outcomes in patients with lymph node metastases from advanced oral cancer.

    DOI: 10.21873/anticanres.13250

    PubMed

    researchmap

  • Is pectus excavatum a risk factor for radiation-induced lung disease in patients undergoing radiation therapy following breast-conserving surgery? Reviewed

    Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Hata M, Sakurai K, Okada M

    Thoracic Cancer   10 ( 2 )   203 - 208   2019.2

     More details

  • Changes in the Ki-67 labeling index between primary breast cancer and metachronous metastatic axillary lymph node: a retrospective observational study. Reviewed

    Ishibashi N, Nishimaki H, Maebayashi T, Hata M, Adachi K, Sakurai K, Masuda S, Okada M

    Thoracic Cancer   10 ( 1 )   96-102   2019.1

     More details

  • Retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab for carcinoma of the buccal mucosa with N3 lymph node metastasis: a case report. Reviewed

    Kaname Sakuma, Toshiyuki Koizumi, Kenji Mitsudo, Jun Ueda, Yuichiro Hayashi, Toshinori Iwai, Makoto Hirota, Mitomu Kioi, Haruka Yoshii, Hisashi Kaizu, Masaharu Hata, Akira Tanaka, Iwai Tohnai

    Oral radiology   35 ( 1 )   77 - 83   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We herein report a case of squamous cell carcinoma of the buccal mucosa with N3 cervical lymph node metastasis in a 63-year-old man. The patient was treated with combination therapy comprising radiotherapy (2 Gy/day, total of 70 Gy), superselective intra-arterial chemotherapy via a superficial temporal artery (docetaxel, total of 70 mg/m2 and cisplatin, total of 175 mg/m2), cetuximab (initial dose of 400 mg/m2 with subsequent weekly doses of 250 mg/m2 intravenously), and four sessions of hyperthermia for cervical lymph node metastases. The patient responded well to the therapy, with a complete response of the primary tumor. Radical neck dissection was performed with reconstructive surgery, including resection of the overlying skin. A pathologic complete response was achieved for the N3 and all other cervical lymph node metastases. The patient showed no evidence of recurrence in the 3 years following treatment. Based on the findings in the present case, the use of retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab seems to be a promising modality for patients with N3 cervical lymph node metastasis of oral cancer.

    DOI: 10.1007/s11282-018-0319-y

    PubMed

    researchmap

  • Oral cavity cancers treated with superselective intra-arterial chemoradiotherapy with radiation doses less than 60Gy: implications for dose reduction from a propensity score matched analysis. Reviewed

    Kaizu H, Hata M, Mitsudo K, Hayashi Y, Ito E, Sugiura M, Takano S, Mukai Y, Koike I, Koizumi T

    International Journal of Radiation Research   in press   2019

     More details

  • Calcium phosphate cement paste injection as a fiducial marker of cervical cancer. Reviewed

    Ogino I, Kitagawa M, Watanabe S, Yoshida H, Hata M

    In Vivo : the International Institute of Anticancer Research / IIAR   32 ( 6 )   1609 - 1615   2018.11

     More details

  • Radio-theranosticsを志向した放射性医薬品開発の現状と展開 Radio-Theranosicsの臨床展開 世界情勢と国内の現状

    高野 祥子, 小林 規俊, 市川 靖史, 上村 博司, 中村 元紀, 堀江 慧一, 安田 尚史, 安藤 賢一, 金田 朋洋, 幡多 政治

    核医学   55 ( Suppl. )   S120 - S120   2018.11

     More details

    Language:English   Publisher:(一社)日本核医学会  

    researchmap

  • Acute and late toxicities in localized prostate cancer patients treated with low-dose 125I brachytherapy (110 Gy) in combination with external beam radiation therapy versus brachytherapy alone (160 Gy). Reviewed International journal

    Mukai Y, Hayashi N, Koike I, Kaizu H, Takano S, Sugiura M, Ito E, Sato M, Uemura H, Yao M, Hata M

    Journal of Contemporary Brachytherapy : an official journal of the Polish Brachytherapy Society and Indian Brachytherapy Society   10 ( 5 )   397 - 404   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Purpose: The aim of this analysis was to compare acute and late toxicities between low-dose-rate brachytherapy (LDR-BT) (110 Gy) in combination with 45 Gy in 25 fractions external beam radiation therapy (EBRT) and LDR-BT (160 Gy) alone for localized prostate cancer. Material and methods: One hundred five consecutive patients with localized prostate cancer treated from May 2014 to May 2017 were included in this retrospective analysis. Sixty patients received combination therapy and 45 patients received BT monotherapy. The LDR-BT procedure was performed using 125I seeds. Results: The median follow-up time was 28 months in both groups. Three-year effect rates were overall survival: 100% in both groups. The biochemical failure rate was 2.3% in the combination group and 0% in the monotherapy group (p = 0.373). No patients died during the study period. In both groups, almost all the patients experienced acute urethritis. There was a significant difference between the combination therapy group (8.3%) and BT monotherapy group (11.1%) in late genitourinary (GU) toxicities ≥ grade 2 (p = 0.035). Only 2 patients (3.3%) in the combination therapy group developed late ≥ grade 2 rectal hemorrhage. There were no significant differences between two groups in hematuria ≥ grade 2 (p = 0.068) or rectal hemorrhage ≥ grade 2 (p = 0.206). Conclusions: To our knowledge, this is the first report to compare the GU and gastrointestinal toxicities between the combination therapy and BT monotherapy (160 Gy) for localized prostate cancer. Unexpectedly, there were more late GU toxicities (except for hematuria) in the BT monotherapy group.

    DOI: 10.5114/jcb.2018.79379

    PubMed

    researchmap

  • 舌癌に対する逆行性超選択的動注化学放射線療法 118例の治療効果の検討

    光藤 健司, 林 雄一郎, 南山 周平, 大橋 伸英, 飯田 昌樹, 岩井 俊憲, 小栗 千里, 小泉 敏之, 來生 知, 廣田 誠, 小池 泉, 幡多 政治, 藤内 祝

    日本癌治療学会学術集会抄録集   56回   P63 - 4   2018.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • The importance of concurrent chemotherapy for T1 esophageal cancer: role of FDG-PET/CT for local control. Reviewed

    Ogino I, Watanabe S, Hirasawa K, Misumi T, Hata M, Kunisaki C

    In Vivo : the International Institute of Anticancer Research / IIAR   32 ( 5 )   1269 - 1274   2018.9

     More details

  • Analysis of prognostic factors, including the incidence of second primary cancer, in patients with early stage laryngeal squamous cell carcinoma treated by radiation-based therapy

    Kaname Sato, Kenichiro Yabuki, Daisuke Sano, Yasuhiro Arai, Yoshihiro Chiba, Teruhiko Tanabe, Goshi Nishimura, Masaharu Hata, Nobuhiko Oridate

    Translational Cancer Research   7 ( 4 )   890 - 900   2018.8

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.21037/tcr.2018.06.15

    Scopus

    researchmap

  • Daily cisplatin and weekly docetaxel versus weekly cisplatin intra-arterial chemoradiotherapy for late T2-3 tongue cancer: a pilot and feasibility trial. Reviewed International journal

    Yuichiro Hayashi, Shuhei Minamiyama, Takashi Ohya, Masaki Iida, Toshinori Iwai, Toshiyuki Koizumi, Senri Oguri, Makoto Hirota, Mitomu Kioi, Masaharu Hata, Masataka Taguri, Kenji Mitsudo

    Medicina (Kaunas, Lithuania)   54 ( 4 )   52   2018.7

     More details

    Language:English  

    Background and objectives: The aim of present study was to compare the treatment results of daily cisplatin (CDDP), weekly docetaxel (DOC) intra-arterial infusion chemotherapy combined with radiotherapy (DIACRT) regimen and weekly CDDP intra-arterial infusion chemotherapy combined with radiotherapy (WIACRT) for patients with tongue cancer. Materials and Methods: Between January 2007 and December 2016, a total of 11 patients treated with WIACRT and 45 patients treated with DIACRT were enrolled in the present study. In the DIACRT group, 25 patients had late T2, and 20 patients had T3. A total of nine patients had late T2 and two had T3 in WIACRT (p = NS). In DIACRT, the treatment schedule consisted of intra-arterial chemotherapy (DOC, total 60 mg/m²; CDDP, total 150 mg/m²) and daily concurrent radiotherapy (RT) (total, 60 Gy). In WIACRT, the treatment schedule consisted of intra-arterial chemotherapy (CDDP, total 360 mg/m²) and daily concurrent RT (total, 60 Gy). Results: The median follow-up periods for DIACRT and WIACRT were 61 and 66 months, respectively. The five-year local control (LC) and overall survival (OS) rate were 94.5% and 89.6% for the DIACRT group, and 60.6% and 63.6% for the WIACRT group, respectively. The LC rate and OS of the DIACRT group were significantly higher than those of the WIACRT group. As regards toxicities, no treatment-related deaths were observed during the follow-up periods in both groups. Conclusions: DIACRT was found to be feasible and effective for patients with tongue cancer and could become a new treatment modality.

    DOI: 10.3390/medicina54040052

    PubMed

    researchmap

  • Treatment outcomes of (chemo)radiotherapy for oropharyngeal cancers: influence of the use of 15 MV X-rays in radiation boost. Reviewed

    Kaizu H, Hata M, Takano S, Kasuya T, Nishimura G, Koike I, Taguchi T, Oridate N

    International Journal of Radiation Research : the Novin Medical Radiation Institute   16 ( 3 )   257 - 267   2018.7

     More details

  • National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG). Reviewed

    Ishibashi N, Soejima T, Kawaguchi H, Akiba T, Hasegawa M, Isobe K, Ito H, Imai M, Ejima Y, Hata M, Sasai K, Shimoda E, Maebayashi T, Oguchi M, Akimoto T

    Journal of Radiation Research   59 ( 4 )   477 - 483   2018.7

     More details

  • Does protruding type 1 esophageal cancer really have a good response to radiation therapy? – a retrospective observational study. Reviewed

    Ishibashi N, Hata M, Maebayashi T, Aizawa T, Sakaguchi M, Okada M

    Journal of Thoracic Disease : an official journal of the China State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health (GIRH), First Affiliated Hospital of Guangzhou Medical University, and Society of Translational Medicine   10 ( 6 )   3512 - 3518   2018.6

     More details

  • Chemoradiotherapy using retrograde superselective intra-arterial infusion for tongue cancer: Analysis of therapeutic results in 118 cases. Reviewed International journal

    Kenji Mitsudo, Yuichiro Hayashi, Shuhei Minamiyama, Nobuhide Ohashi, Masaki Iida, Toshinori Iwai, Senri Oguri, Toshiyuki Koizumi, Mitomu Kioi, Makoto Hirota, Izumi Koike, Masaharu Hata, Iwai Tohnai

    Oral oncology   79   71 - 77   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: To evaluate the therapeutic results and rate of organ preservation in patients with squamous cell carcinoma of the tongue treated with retrograde superselective intra-arterial chemoradiotherapy. MATERIALS AND METHODS: Between June 2006 and June 2015, 118 patients with tongue cancer were treated with intra-arterial chemoradiotherapy. Treatment consisted of radiotherapy (total 50-70 Gy) and daily concurrent intra-arterial chemotherapy (docetaxel, total 50-70 mg/m2; cisplatin, total 125-175 mg/m2) for 5-7 weeks. Locoregional control and overall survival rates were calculated by the Kaplan-Meier method. Cox's proportional hazards model was used for both univariate and multivariate analyses. RESULTS: The median follow-up for all patients was 38.5 months (range, 3-129 months). After intra-arterial chemoradiotherapy, primary site complete response was achieved in 113 (95.8%) of 118 cases. Three-year locoregional control and overall survival rates were 80.3% and 81.5%, respectively. Grade 3 or 4 toxicities included neutropenia in 16.1% and mucositis in 87.3%. Grade 3 toxicities included anemia in 12.7%, thrombocytopenia in 3.4%, nausea/vomiting in 3.4%, dermatitis in 45.7%, dysphagia in 74.6%, and fever in 2.5% of patients. Late toxicity consisting of grade 3 osteoradionecrosis of the jaw occurred in 4.2% of patients. On univariate analysis, T stage and overall stage were significantly associated with locoregional control, and N stage and overall stage were significantly associated with overall survival. On multivariate analysis, the only significant predictor of overall survival was overall stage classification. CONCLUSION: Retrograde superselective intra-arterial chemoradiotherapy for tongue cancer provided good overall survival and locoregional control.

    DOI: 10.1016/j.oraloncology.2018.02.002

    PubMed

    researchmap

  • Radiation therapy for angiosarcoma of the scalp: Total scalp irradiation and local irradiation Reviewed

    Masaharu Hata

    Anticancer Research   38 ( 3 )   1247 - 1253   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:International Institute of Anticancer Research  

    DOI: 10.21873/anticanres.12346

    Scopus

    PubMed

    researchmap

  • Treatment outcome for locally advanced non-small-cell lung cancer using TomoDirect plan and its characteristics compared to the TomoHelical plan Reviewed

    Yuki Mukai, Motoko Omura, Harumitu Hashimoto, Kengo Matsui, Hideyuki Hongo, Wataru Yamakabe, Miwa Yoshida, Masaharu Hata, Tomio Inoue

    Journal of Medical Radiation Sciences   65 ( 1 )   55 - 62   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:John Wiley and Sons Ltd  

    DOI: 10.1002/jmrs.265

    Scopus

    researchmap

  • Radiation therapy for patients with bone metastasis from uterine cervical cancer: Its role and optimal radiation regimen for palliative care Reviewed

    Masaharu Hata, Izumi Koike, Etsuko Miyagi, Mikiko Asai-Sato, Hisashi Kaizu, Yuki Mukai, Shoko Takano, Eiko Ito, Madoka Sugiura, Tomio Inoue

    Anticancer Research   38 ( 2 )   1033 - 1040   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:International Institute of Anticancer Research  

    DOI: 10.21873/anticanres.12319

    Scopus

    PubMed

    researchmap

  • Daily concurrent chemoradiotherapy using retrograde superselective intra-arterial infusion for locally advanced squamous cell carcinoma of the mandibular gingiva Reviewed

    Senri Oguri, Kenji Mitsudo, Masaki Iida, Toshinori Iwai, Toshiyuki Koizumi, Makoto Hirota, Mitomu Kioi, Izumi Koike, Masaharu Hata, Iwai Tohnai

    Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology   30 ( 6 )   483 - 487   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier Ltd  

    DOI: 10.1016/j.ajoms.2018.05.002

    Scopus

    researchmap

  • Radiation therapy for orbital mucosa-associated lymphoid tissue lymphoma: What is the optimal radiation dose? Reviewed

    Hata M

    Annals of Radiation Therapy and Oncology   1 ( 3 )   1012   2017.12

     More details

  • 内用療法の普及と安全利用~多職種の立場から~ 新規RI内用療法薬剤の導入と多職種連携 当院の取り組み

    高野 祥子, 杉浦 円, 高田 由貴, 有澤 哲, 金田 朋洋, 幡多 政治, 小林 規俊, 市川 靖史, 尾川 松義, 臼井 淳之, 大沼 教子, 立石 由佳, 木藤 理恵, 山中 竹春, 井上 登美夫

    核医学   54 ( Suppl. )   S65 - S65   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

    researchmap

  • 内用療法の普及と安全利用 他職種の立場から 新規RI内用療法薬剤の導入と多職種連携 当院の取り組み

    高野 祥子, 杉浦 円, 高田 由貴, 有澤 哲, 金田 朋洋, 幡多 政治, 小林 規俊, 市川 靖史, 尾川 松義, 臼井 淳之, 大沼 教子, 立石 由佳, 木藤 理恵, 山中 竹春, 井上 登美夫

    核医学技術   37 ( 予稿集 )   405 - 405   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

    researchmap

  • Clinical outcomes of retrograde intraarterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old Reviewed

    Yuichiro Hayashi, Kenji Mitsudo, Kaname Sakuma, Masaki Iida, Toshinori Iwai, Hideyuki Nakashima, Yoshiyuki Okamoto, Toshiyuki Koizumi, Senri Oguri, Makoto Hirota, Mitomu Kioi, Izumi Koike, Masaharu Hata, Iwai Tohnai

    Radiation Oncology   12 ( 1 )   112   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s13014-017-0847-3

    Web of Science

    researchmap

  • Surgery-based versus radiation-based treatment strategy for a high metabolic volume laryngeal cancer. Reviewed

    Yabuki K, Sano D, Shiono O, Arai Y, Chiba Y, Tanabe T, Nishimura G, Takahashi M, Taguchi T, Kaneta T, Hata M, Oridate N

    The Laryngoscope : an official journal of the American Laryngological, Rhinological and Otological Society   127 ( 4 )   862 - 867   2017.4

     More details

    Language:English  

    researchmap

  • Radiation Therapy for Very Elderly Patients Aged 80 Years and Older With Squamous Cell Carcinoma of the Uterine Cervix Reviewed

    Masaharu Hata, Izumi Koike, Etsuko Miyagi, Reiko Numazaki, Mikiko Asai-Sato, Takeo Kasuya, Hisashi Kaizu, Tonika Matsui, Fumiki Hirahara, Tomio Inoue

    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS   40 ( 2 )   178 - 182   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/COC.0000000000000125

    Web of Science

    researchmap

  • Radiation therapy for stage IVA uterine cervical cancer: Treatment outcomes including prognostic factors and risk of vesicovaginal and rectovaginal fistulas Reviewed

    Masaharu Hata, Izumi Koike, Etsuko Miyagi, Reiko Numazaki, Mikiko Asai-Sato, Hisashi Kaizu, Yuki Mukai, Shoko Takano, Eiko Ito, Madoka Sugiura, Tomio Inoue

    Oncotarget   8 ( 68 )   112855 - 112866   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Impact Journals LLC  

    DOI: 10.18632/oncotarget.22836

    Scopus

    researchmap

  • Prognostic significance of metabolic tumor volume in patients with piriform sinus carcinoma treated by radiotherapy with or without concurrent chemotherapy. Reviewed International journal

    Kenichiro Yabuki, Daisuke Sano, Osamu Shiono, Yasuhiro Arai, Hideaki Takahashi, Yoshihiro Chiba, Teruhiko Tanabe, Goshi Nishimura, Masahiro Takahashi, Takahide Taguchi, Tomohiro Kaneta, Masaharu Hata, Nobuhiko Oridate

    Head & neck   38 ( 11 )   1666 - 1671   2016.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The purpose of this study was to elucidate the prognostic significance of the pretreatment metabolic tumor volume (MTV) in patients with piriform sinus carcinoma treated by radiation-based therapy. METHODS: This retrospective study included 100 patients with piriform sinus carcinomas who had received treatment by radiation-based therapy. The MTV values were obtained from pretreatment positron emission tomography (PET). The association between clinical factors, including the MTV, and survival was analyzed. RESULTS: Kaplan-Meier estimates revealed the 5-year disease-free survival (DFS) rates were significantly poorer for patients with a high MTV compared to those with a low MTV. In the multivariate analysis, MTV (p < .001), nodal metastasis (p = .011), and applied chemotherapy regimen (p = .004) were found to be independent prognostic factors for DFS. CONCLUSION: The locoregional MTV is a prognostic factor for DFS in patients with piriform sinus carcinoma treated by radiation-based therapy. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1708-1716, 2016.

    DOI: 10.1002/hed.24488

    PubMed

    J-GLOBAL

    researchmap

  • Radiation therapy for primary breast lymphoma in male gynecomastia: a rare case report and review of the literature. Reviewed

    Ishibashi N, Hata M, Mochizuki T, Ogawa K, Sugiura H, Takekawa Y, Maebayashi T, Aizawa T, Sakaguchi M, Abe O

    International Journal of Hematology   104 ( 4 )   524   2016.10

     More details

  • Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma. Reviewed

    Nishimura G, Yabuki K, Hata M, Komatsu M, Taguchi T, Takahashi M, Shiono O, Sano D, Arai Y, Takahashi H, Chiba Y, Oridate N

    International Journal of Clinical Oncology   21 ( 4 )   667   2016.8

  • Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma. Reviewed International journal

    Goshi Nishimura, Takahide Taguchi, Masahiro Takahashi, Osamu Shiono, Masanori Komatsu, Daisuke Sano, Kenichiro Yabuki, Yasuhiro Arai, Hideaki Takahashi, Masaharu Hata, Nobuhiko Oridate

    Cancer chemotherapy and pharmacology   77 ( 6 )   1315 - 9   2016.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Although locally advanced head and neck squamous cell carcinoma (HNSCC) can be effectively treated using chemoradiotherapy (CRT) with docetaxel (DTX), and cisplatin (CDDP) plus 5-fluorouracil (TPF-CRT), severe adverse events (especially neutropenia) can limit treatment adherence. Therefore, we evaluated the safety and efficacy of a new chemotherapy regimen that consisted of DTX and CDDP plus cetuximab (Cmab) with concurrent radiotherapy. METHODS: Bio-chemoradiotherapy (B-CRT) using DTX, CDDP, and Cmab was administrated to patients with locally advanced HNSCC, and its safety and efficacy were evaluated. RESULTS: Interim analysis of nine patients revealed severe neutropenia in five patients (56 %) and leukopenia in seven patients (78 %); hence, the study was terminated. One patient experienced disease-free survival using only B-CRT. CONCLUSIONS: Neutropenia was equally severe for B-CRT, compared to TPF-CRT. Based on the limited sample size, it is impossible to conclude that B-CRT has non-inferior efficacy, compared to TPF-CRT.

    DOI: 10.1007/s00280-016-3052-4

    PubMed

    J-GLOBAL

    researchmap

  • Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy. Reviewed

    Nishimura G, Komatsu M, Hata M, Yabuki K, Taguchi T, Takahashi M, Shiono O, Sano D, Arai Y, Takahashi H, Chiba Y, Oridate N

    International Journal of Clinical Oncology   21 ( 2 )   230   2016.4

  • Ten-year outcomes of I-125 low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan Reviewed

    Narihiko Hayashi, Koji Izumi, Futoshi Sano, Yasuhide Miyoshi, Hiroji Uemura, Takeo Kasuya, Akiko Mukai, Masayuki Hata, Tomio Inoue

    WORLD JOURNAL OF UROLOGY   33 ( 10 )   1519 - 1526   2015.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00345-015-1480-0

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Radiation therapy for para-aortic lymph node metastasis from uterine cervical cancer. Reviewed

    Hata M, Miyagi E, Koike I, Numazaki R, Asai-Sato M, Kasuya T, Kaizu H, Mukai Y, Hirahara F, Inoue T

    Anticancer Research : the International Institute of Anticancer Research / IIAR   35 ( 9 )   4849 - 4854   2015.9

     More details

  • Postoperative radiation therapy for extramammary Paget's disease Reviewed

    M. Hata, I. Koike, H. Wada, E. Miyagi, T. Kasuya, H. Kaizu, Y. Mukai, T. Inoue

    BRITISH JOURNAL OF DERMATOLOGY   172 ( 4 )   1014 - 1020   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/bjd.13357

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • High-dose proton beam therapy for stage I non-small cell lung cancer: Clinical outcomes and prognostic factors. Reviewed International journal

    Chiyoko Makita, Tatsuya Nakamura, Akinori Takada, Kanako Takayama, Motohisa Suzuki, Yusuke Azami, Takahiro Kato, Iwao Tsukiyama, Masato Hareyama, Yasuhiro Kikuchi, Takashi Daimon, Masaharu Hata, Tomio Inoue, Nobukazu Fuwa

    Acta oncologica (Stockholm, Sweden)   54 ( 3 )   307 - 14   2015.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Evidence has suggested that radiation therapy with a lower dose per fraction may be a reasonable option for the treatment of centrally located non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of two proton beam therapy (PBT) protocols for stage I NSCLC and to determine prognostic factors. MATERIAL AND METHODS: This study included patients clinically diagnosed with stage I NSCLC. Based on the location of the tumor, one of the two PBT protocols was administered. Patients with peripherally located tumors were given 66 Gy relative biological dose effectiveness (RBE) over 10 fractions (Protocol A) while patients with centrally located tumors were given 80 Gy (RBE) over 25 fractions (Protocol B). RESULTS: Between January 2009 and May 2012, 56 eligible patients were enrolled (protocol A: 32 patients; protocol B: 24 patients). The three-year overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 81.3% [95% confidence interval (CI) 75.9-86.7%], 73.4% (95% CI 67.2-79.6%), and 96.0% (95% CI 93.2-98.8%), respectively. There were no significant differences in outcomes between the two protocols. Late grade 2 and 3 pulmonary toxicities were observed in nine patients (13.4%) and one patient (1.5%), respectively; no grade 4 or 5 toxicities were observed. Sex, age, performance status, T-stage, operability, and tumor pathology were not associated with OS and PFS. Only maximum standardized uptake value (SUVmax; <5 vs. ≥5) was identified as a significant prognostic factor for OS and PFS. CONCLUSION: Both high-dose PBT protocols achieved high LC rates with tolerable toxicities in stage I NSCLC patients, and SUVmax was a significant prognostic factor.

    DOI: 10.3109/0284186X.2014.948060

    PubMed

    researchmap

  • Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (&lt; 12 g/dL) and post-radiation therapy F-18 FDG-PET/CT Reviewed

    Ryoko Katahira-Suzuki, Masaharu Hata, Ukihide Tateishi, Takahide Taguchi, Shoko Takano, Motoko Omura-Minamisawa, Tomio Inoue

    ANNALS OF NUCLEAR MEDICINE   29 ( 1 )   37 - 45   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12149-014-0907-9

    Web of Science

    PubMed

    researchmap

  • Severe retinopathy following radiation therapy with a moderate dose for orbital mucosa-associated lymphoid tissue lymphoma Reviewed

    Masaharu Hata, Akihiro Kaneko, Naoto Tomita, Tomio Inoue

    HEMATOLOGICAL ONCOLOGY   32 ( 4 )   212 - 214   2014.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hon.2124

    Web of Science

    PubMed

    researchmap

  • Phase II Study of Concurrent Chemoradiotherapy with S-1 in Patients with Stage II (T2N0M0) Squamous Cell Carcinoma of the Pharynx or Larynx Reviewed

    Takahide Taguchi, Masahiro Takahashi, Goshi Nishimura, Osamu Shiono, Masanori Komatsu, Daisuke Sano, Yasunori Sakuma, Yuji Tanigaki, Akira Kubota, Masataka Taguri, Masaharu Hata, Nobuhiko Oridate

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   44 ( 12 )   1158 - 1163   2014.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jjco/hyu154

    Web of Science

    PubMed

    researchmap

  • 咽頭扁平上皮癌の根治的化学放射線治療 治療前Hb値(≧12g/dl)と治療後PET-CTの重要性

    鈴木 涼子, 幡多 政治, 立石 宇貴秀, 井上 登美夫, 田口 享秀, 高野 祥子, 大村 素子

    核医学   51 ( 4 )   432 - 432   2014.11

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

    researchmap

  • Radiation therapy for angiosarcoma of the scalp Treatment outcomes of total scalp irradiation with X-rays and electrons Reviewed

    Masaharu Hata, Hidefumi Wada, Ichiro Ogino, Motoko Omura, Izumi Koike, Yoshibumi Tayama, Kazumasa Odagiri, Takeo Kasuya, Tomio Inoue

    STRAHLENTHERAPIE UND ONKOLOGIE   190 ( 10 )   899 - 904   2014.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-014-0627-z

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Iris Metastasis from Small-Cell Lung Cancer Reviewed

    Masaharu Hata, Tomio Inoue

    JOURNAL OF THORACIC ONCOLOGY   9 ( 10 )   1584 - 1585   2014.10

  • Treatment outcomes and late toxicities in patients with embryonal central nervous system tumors Reviewed

    Kazumasa Odagiri, Motoko Omura, Masaharu Hata, Noriko Aida, Tetsu Niwa, Hiroaki Goto, Susumu Ito, Masanori Adachi, Haruyasu Yoshida, Hiroko Yuki, Tomio Inoue

    RADIATION ONCOLOGY   9 ( 1 )   201   2014.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/1748-717X-9-201

    Web of Science

    PubMed

    researchmap

  • Radiation therapy for lymph node metastasis from extramammary Paget's disease Reviewed

    M. Hata, I. Koike, H. Wada, Y. Minagawa, T. Kasuya, T. Matsui, R. Suzuki, S. Takano, T. Inoue

    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY   28 ( 7 )   873 - 877   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/jdv.12185

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Relative biological effectiveness of therapeutic proton beams for HSG cells at Japanese proton therapy facilities Reviewed

    Mizuho Aoki-Nakano, Yoshiya Furusawa, Akiko Uzawa, Yoshitaka Matsumoto, Ryoichi Hirayama, Chizuru Tsuruoka, Takashi Ogino, Teiji Nishio, Kazufumi Kagawa, Masao Murakami, Go Kagiya, Kyo Kume, Masanori Hatashita, Shigekazu Fukuda, Kazutaka Yamamoto, Hiroshi Fuji, Shigeyuki Murayama, Masaharu Hata, Takeji Sakae, Hideki Matsumoto

    JOURNAL OF RADIATION RESEARCH   55 ( 4 )   812 - 815   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jrr/rru003

    Web of Science

    PubMed

    researchmap

  • Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy Reviewed

    Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Ken-ichiro Yabuki, Yasuhiro Arai, Hideaki Takahashi, Masaharu Hata, Izumi Koike, Nobuhiko Oridate

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   73 ( 6 )   1147 - 1154   2014.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00280-014-2448-2

    Web of Science

    PubMed

    researchmap

  • Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: Analysis of therapeutic results in 112 cases Reviewed

    Kenji Mitsudo, Toshiyuki Koizumi, Masaki Iida, Toshinori Iwai, Hideyuki Nakashima, Senri Oguri, Mitomu Kioi, Makoto Hirota, Izumi Koike, Masaharu Hata, Iwai Tohnai

    RADIOTHERAPY AND ONCOLOGY   111 ( 2 )   306 - 310   2014.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.radonc.2014.03.005

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Radiation therapy with concurrent retrograde superselective intra-arterial chemotherapy for gingival carcinoma Reviewed

    Y. Mukai, M. Hata, K. Mitsudo, I. Koike, T. Koizumi, S. Oguri, M. Kioi, M. Omura, I. Tohnai, T. Inoue

    STRAHLENTHERAPIE UND ONKOLOGIE   190 ( 2 )   181 - 185   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-013-0468-1

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Malignant melanoma of the lacrimal sac: a case report Reviewed

    Jiro Maegawa, Kazunori Yasumura, Toshinori Iwai, Masaharu Hata, Yoshiaki Inayama, Shinji Kobayashi

    INTERNATIONAL JOURNAL OF DERMATOLOGY   53 ( 2 )   243 - 245   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1365-4632.2012.05480.x

    Web of Science

    PubMed

    researchmap

  • Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors Reviewed

    M. Hata, I. Koike, H. Wada, E. Miyagi, T. Kasuya, H. Kaizu, T. Matsui, Y. Mukai, E. Ito, T. Inoue

    ANNALS OF ONCOLOGY   25 ( 1 )   291 - 297   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/annonc/mdt478

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma Reviewed

    Chiyoko Makita, Tatsuya Nakamura, Akinori Takada, Kanako Takayama, Motohisa Suzuki, Yojiro Ishikawa, Yusuke Azami, Takahiro Kato, Iwao Tsukiyama, Yasuhiro Kikuchi, Masato Hareyama, Masao Murakami, Nobukazu Fuwa, Masaharu Hata, Tomio Inoue

    RADIATION ONCOLOGY   9 ( 1 )   26   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/1748-717X-9-26

    Web of Science

    PubMed

    researchmap

  • Small-cell undifferentiated (neuroendocrine) carcinoma of the nasal cavity treated with concurrent chemoradiotherapy including irinotecan and cisplatin. Reviewed

    Taguchi T, Isono Y, Sakuma N, Komatsu M, Nishimura G, Takahashi M, Inayama Y, Omura M, Hata M, Oridate N

    International Cancer Conference Journal   3 ( 1 )   11 - 15   2014.1

     More details

  • Chemoradiation as a definitive treatment for cervical lymph node metastases from unknown primary cancer Reviewed

    Hisashi Kaizu, Ichiro Ogino, Masaharu Hata, Mari S. Oba, Osamu Shiono, Masanori Komatsu, Tomio Inoue

    Anticancer Research   33 ( 11 )   5187 - 5192   2013.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Radiation therapy for pelvic lymph node metastasis from uterine cervical cancer Reviewed

    Masaharu Hata, Izumi Koike, Etsuko Miyagi, Reiko Numazaki, Mikiko Asai-Sato, Takeo Kasuya, Hisashi Kaizu, Tonika Matsui, Fumiki Hirahara, Tomio Inoue

    GYNECOLOGIC ONCOLOGY   131 ( 1 )   99 - 102   2013.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ygyno.2013.07.085

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy Reviewed

    Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Yasuhiro Arai, Yukiko Yamashita, Osamu Shiono, Mariko Hirama, Yasunori Sakuma, Jun-ichi Ishitoya, Masaharu Hata, Ichiro Ogino, Nobuhiko Oridate

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   72 ( 4 )   837 - 843   2013.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00280-013-2261-3

    Web of Science

    PubMed

    researchmap

  • Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer Reviewed

    M. Hata, T. Taguchi, I. Koike, G. Nishimura, M. Takahashi, M. Komatsu, D. Sano, K. Odagiri, Y. Minagawa, T. Inoue

    STRAHLENTHERAPIE UND ONKOLOGIE   189 ( 1 )   26 - 32   2013.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-012-0178-0

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Role of respiratory-gated PET/CT for pancreatic tumors: A preliminary result Reviewed

    Takeo Kasuya, Ukihide Tateishi, Kazufumi Suzuki, Hiromitsu Daisaki, Yuji Nishiyama, Masaharu Hata, Tomio Inoue

    EUROPEAN JOURNAL OF RADIOLOGY   82 ( 1 )   69 - 74   2013.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ejrad.2012.05.037

    Web of Science

    PubMed

    researchmap

  • Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function Reviewed

    M. Hata, I. Koike, J. Maegawa, A. Kaneko, K. Odagiri, T. Kasuya, Y. Minagawa, H. Kaizu, Y. Mukai, T. Inoue

    STRAHLENTHERAPIE UND ONKOLOGIE   188 ( 12 )   1102 - 1107   2012.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-012-0145-9

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Treatment Outcomes, Growth Height, and Neuroendocrine Functions in Patients With Intracranial Germ Cell Tumors Treated With Chemoradiation Therapy Reviewed

    Kazumasa Odagiri, Motoko Omura, Masaharu Hata, Noriko Aida, Tetsu Niwa, Ichiro Ogino, Hisato Kigasawa, Susumu Ito, Masataka Adachi, Tomio Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   84 ( 3 )   632 - 638   2012.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2011.12.084

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Definitive radiation therapy for extramammary Paget's disease. Reviewed

    Hata M, Koike I, Wada H, Miyagi E, Odagiri K, Minagawa Y, Kasuya T, Kaizu H, Inoue T

    Anticancer Research : the International Institute of Anticancer Research / IIAR   32 ( 8 )   3315 - 3320   2012.8

     More details

  • NONINVASIVE AND CURATIVE RADIATION THERAPY FOR SEBACEOUS CARCINOMA OF THE EYELID Reviewed

    Masaharu Hata, Izumi Koike, Motoko Omura, Jiro Maegawa, Ichiro Ogino, Tomio Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   82 ( 2 )   605 - 611   2012.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2010.12.006

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • The Role of Radiation Therapy for Uterine Cervical Cancer with Distant Metastasis Reviewed

    Masaharu Hata, Motoko Omura, Etsuko Miyagi, Izumi Koike, Reiko Numazaki, Mikiko Asai-Sato, Yoshibumi Tayama, Ichiro Ogino, Fumiki Hirahara, Tomio Inoue

    ONCOLOGY   83 ( 2 )   67 - 74   2012

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1159/000337985

    Web of Science

    PubMed

    researchmap

  • TREATMENT EFFECTS AND SEQUELAE OF RADIATION THERAPY FOR ORBITAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA Reviewed

    Masaharu Hata, Motoko Omura, Izumi Koike, Naoto Tomita, Yasuhito Iijima, Yoshibumi Tayama, Kazumasa Odagiri, Yumiko Minagawa, Ichiro Ogino, Tomio Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   81 ( 5 )   1387 - 1393   2011.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2010.07.1992

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • 核医学の進歩と展望 PET導入後の新たな展開 放射線治療への応用

    立石 宇貴秀, 幡多 政治, 井上 登美夫

    日本医学会総会会誌   28回 ( II )   91 - 91   2011.10

     More details

    Language:Japanese   Publisher:日本医学会  

    researchmap

  • Assessment of tumor hypoxia by Cu-62-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study Reviewed

    Yumiko Minagawa, Kazuya Shizukuishi, Izumi Koike, Choichi Horiuchi, Kei Watanuki, Masaharu Hata, Motoko Omura, Kazumasa Odagiri, Iwai Tohnai, Tomio Inoue, Ukihide Tateishi

    ANNALS OF NUCLEAR MEDICINE   25 ( 5 )   339 - 345   2011.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12149-011-0471-5

    Web of Science

    PubMed

    researchmap

  • ROLE OF RADIOTHERAPY AS CURATIVE TREATMENT OF EXTRAMAMMARY PAGET'S DISEASE Reviewed

    Masaharu Hata, Motoko Omura, Izumi Koike, Hidefumi Wada, Etsuko Miyagi, Yoshibumi Tayama, Kazumasa Odagiri, Yumiko Minagawa, Ichiro Ogino, Tomio Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   80 ( 1 )   47 - 54   2011.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2010.01.073

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma Reviewed

    Ryogo Minamimoto, Ukihide Tateishi, Naoto Tomita, Yoshiaki Inayama, Motoko Omura-Minamisawa, Yoshibumi Tayama, Masaharu Hata, Yoshinobu Kubota, Tomio Inoue

    ANNALS OF NUCLEAR MEDICINE   24 ( 2 )   115 - 119   2010.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12149-009-0335-4

    Web of Science

    PubMed

    researchmap

  • Malignant myoepithelioma in the maxillary sinus: case report and review of the literature. Reviewed

    Hata M, Tokuuye K, Shioyama Y, Nomoto S, Inadome Y, Fukumitsu N, Nakayama H, Sugahara S, Ohara K, Noguchi M, Akine Y

    Anticancer Research : the International Institute of Anticancer Research / IIAR   29 ( 2 )   497 - 501   2009.2

     More details

  • Proton beam therapy for aged patients with hepatocellular carcinoma. Reviewed

    Hata M, Tokuuye K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y

    International Journal of Radiation Oncology, Biology, Physics : an official journal of the American Society for Radiation Oncology / ASTRO   69 ( 3 )   805 - 812   2007.11

  • Proton beam therapy for aged patients with hepatocellular carcinoma Reviewed

    Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Eriko Tohno, Hidetsugu Nakayama, Nobuyoshi Fukumitsu, Masashi Mizumoto, Masato Abei, Junichi Shoda, Manabu Minami, Yasuyuki Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   69 ( 3 )   805 - 812   2007.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE INC  

    Purpose: To investigate the safety and efficacy of proton beam therapy for aged patients with hepatocellular carcinoma (HCC).
    Methods and Materials: Twenty-one patients aged &gt;= 80 years with HCC underwent proton beam therapy. At the time of irradiation, patient age ranged from 80 to 85 years (median, 81 years). Hepatic tumors were solitary in 17 patients and multiple in 4. Tumor size ranged from 10 to 135 mm (median, 40 mm) in maximum diameter. Ten, 5, and 6 patients received proton beam irradiation with total doses of 60 Gy in 10 fractions, 66 Gy in 22 fractions, and 70 Gy in 35 fractions, respectively, according to tumor location.
    Results: All irradiated tumors were controlled during the follow-up period of 6-49 months (median, 16 months). Five patients showed new hepatic tumors outside the irradiated volume, 2-13 months after treatment, and 1 of them also had lung metastasis. The local progression-free and disease-free rates were 100% and 72% at 3 years, respectively. Of 21 patients, 7 died 6-49 months after treatment; 2 patients each died of trauma and old age, and 1 patient each died of HCC, pneumonia, and arrhythmia. The 3-year overall, cause-specific, and disease-free survival rates were 62%,88%, and 51%, respectively. No therapy-related toxicity of Grade &gt;= 3 but thrombocytopenia in 2 patients was observed.
    Conclusions: Proton beam therapy seems to be tolerable, effective, and safe for aged patients with HCC. It may contribute to prolonged survival due to tumor control. (C) 2007 Elsevier Inc.

    DOI: 10.1016/j.ijrobp.2007.04.016

    Web of Science

    researchmap

  • Classical tandem-source dwelling covering the entire uterus: Essential in modern intracavitary radiotherapy for cervical cancer? Reviewed

    Kiyoshi Ohara, Keiko Nemoto, Kayoko Ohnishi, Takayuki Hashimoto, Nobuyoshi Fukumitsu, Masaharu Hata, Shinji Sugahara, Koichi Tokuuye, Yasuyuki Akine

    Radiation Medicine - Medical Imaging and Radiation Oncology   25 ( 8 )   386 - 392   2007.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11604-007-0154-2

    Scopus

    PubMed

    researchmap

  • Proton irradiation in a single fraction for hepatocellular carcinoma patients with uncontrollable ascites Reviewed

    Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Eriko Tohno, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Takeji Sakae, Yasuyuki Akine

    STRAHLENTHERAPIE UND ONKOLOGIE   183 ( 8 )   411 - 416   2007.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-007-1640-2

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: Preliminary results of a phase I/II clinical study Reviewed

    Masaharu Hata, Koichi Tokuuye, Kenji Kagei, Shinji Sugahara, Hidetsugu Nakayama, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Masashi Mizumoto, Kiyoshi Ohara, Yasuyuki Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   68 ( 3 )   786 - 793   2007.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2006.12.063

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: Report of three cases Reviewed

    Masashi Mizumoto, Koichi Tokuuye, Shinji Sugahara, Masaharu Hata, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Yasushi Matsuzaki, Eriko Tohno, Yasuyuki Akine

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   37 ( 6 )   459 - 462   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jjco/hym038

    Web of Science

    PubMed

    researchmap

  • Explanation for the failure of neoadjuvant chemotherapy to improve outcomes after radiotherapy for locally advanced uterine cervical cancer from the standpoint of the tumor regression rate Reviewed

    Kiyoshi Ohara, Hajime Tsunoda, Yumiko Oishi Tanaka, Kayoko Ohnishi, Keiko Nemoto, Takayuki Hashimoto, Nobuyoshi Fukumitsu, Masaharu Hata, Shinji Sugahara, Koichi Tokuuye, Hiroyuki Yoshikawa, Yasuyuki Akine

    Radiation Medicine - Medical Imaging and Radiation Oncology   25 ( 2 )   53 - 59   2007.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11604-006-0101-7

    Scopus

    PubMed

    researchmap

  • Biological intercomparison using gut crypt survivals for proton and carbon-ion beams. Reviewed

    Uzawa A, Ando K, Furusawa Y, Kagiya G, Fuji H, Hata M, Sakae T, Terunuma T, Scholz M, Ritter S, Peschke P

    Journal of Radiation Research   48 Suppl A   A75 - 80   2007

  • Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis Reviewed

    Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Yasushi Matsuzaki, Yasuyuki Akine

    STRAHLENTHERAPIE UND ONKOLOGIE   182 ( 12 )   713 - 720   2006.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-006-1564-2

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • A patient surviving for eight years after proton and x-ray irradiation for advanced esophageal cancer Reviewed

    Nobuyoshi Fukumitsu, Koichi Tokuuye, Shinji Sugahara, Takayuki Hashimoto, Masaharu Hata, Kiyoshi Ohara, Takeshi Shibahara, Akira Nakahara, Yasuyuki Akine

    ACTA ONCOLOGICA   45 ( 8 )   1132 - 1134   2006.12

  • Sequential evaluation of hepatic functional reserve by (99m)Technetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures Reviewed

    Hiroshi Igaki, Koichi Tokuuye, Tohoru Takeda, Shinji Sugahara, Masaharu Hata, Takayuki Hashimoto, Nobuyoshi Fukumitsu, Jin Wu, Kayoko Ohnishi, Kiyoshi Ohara, Yasuyuki Akine

    ACTA ONCOLOGICA   45 ( 8 )   1102 - 1107   2006.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/02841860600690347

    Web of Science

    PubMed

    researchmap

  • Proton beam therapy for hepatocellular carcinoma with limited treatment options Reviewed

    Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Yasushi Matsuzaki, Yasuyuki Akine

    CANCER   107 ( 3 )   591 - 598   2006.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cncr.22039

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Repeated proton beam therapy for hepatocellular carcinoma Reviewed

    T Hashimoto, K Tokuuye, N Fukumitsu, H Igaki, M Hata, K Kagei, S Sugahara, K Ohara, Y Matsuzaki, Y Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   65 ( 1 )   196 - 202   2006.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2005.11.043

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Proton beam therapy for invasive bladder cancer: A prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy Reviewed

    M Hata, N Miyanaga, K Tokuuye, Y Saida, K Ohara, S Sugahara, K Kagei, H Igaki, T Hashimoto, K Hattori, T Shimazu, H Akaza, Y Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   64 ( 5 )   1371 - 1379   2006.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2005.10.023

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors Reviewed

    K Ohara, A Oki, YO Tanaka, K Onishi, N Fukumitsu, T Hashimoto, T Satoh, H Tsunoda, M Hata, S Sugahara, K Tokuuye, Y Akine, H Yoshikawa

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   64 ( 4 )   1179 - 1182   2006.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2005.09.022

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus Reviewed

    M Hata, K Tokuuye, S Sugahara, K Kagei, H Igaki, T Hashimoto, K Ohara, Y Matsuzaki, N Tanaka, Y Akine

    CANCER   104 ( 4 )   794 - 801   2005.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cncr.21237

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Reviewed

    Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, Shoda J, Hata M, Abei M, Igaki H, Tanaka N, Akine Y

    Clinical cancer research : an official journal of the American Association for Cancer Research   11 ( 10 )   3799 - 3805   2005.5

  • Preliminary estimation of treatment effect on uterine cervical squamous cell carcinoma in terms of tumor regression rate: Comparison between chemoradiotherapy and radiotherapy alone Reviewed

    Kiyoshi Ohara, Yumiko Oishi Tanaka, Hajime Tsunoda, Akinori Oki, Toyomi Satoh, Kayoko Onishi, Kenji Kagei, Shinji Sugahara, Masaharu Hata, Hiroshi Igaki, Koichi Tokuuye, Yasuyuki Akine, Hiroyuki Yoshikawa

    Radiation Medicine - Medical Imaging and Radiation Oncology   23 ( 1 )   25 - 29   2005.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Clinical results of proton beam therapy for cancer of the esophagus Reviewed

    S Sugahara, K Tokuuye, T Okumura, A Nakahara, Y Saida, K Kagei, K Ohara, M Hata, H Igaki, Y Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   61 ( 1 )   76 - 84   2005.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2004.04.003

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Clinical results of proton beam therapy for skull base chordoma Reviewed

    H Igaki, K Tokuuye, T Okumura, S Sugahara, K Kagei, M Hata, K Ohara, T Hashimoto, K Tsuboi, S Takano, A Matsumura, Y Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   60 ( 4 )   1120 - 1126   2004.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijrobp.2004.05.054

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Initial experience of proton beam therapy at the new facility of the University of Tsukuba Reviewed

    Kagei Kenji, Tokuuye Koichi, Sugahara Shinji, Hata Masaharu, Igaki Hiroshi, Hashimoto Takayuki, Ohara Kiyoshi, Akine Yasuyuki

    Nippon Acta Radiologica   64 ( 4 )   225 - 230   2004.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Proton therapy for head and neck malignancies at Tsukuba Reviewed

    K Tokuuye, Y Akine, K Kagei, M Hata, T Hashimoto, T Mizumoto, Y Ohshiro, S Sugahara, K Ohara, T Okumura, J Kusakari, H Yoshida, F Otsuka

    STRAHLENTHERAPIE UND ONKOLOGIE   180 ( 2 )   96 - +   2004.2

     More details

    Language:German   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-004-1132-6

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Asymptomatic radiation-induced telangiectasia in children after cranial irradiation: Frequency, latency, and dose relation Reviewed

    S Koike, N Aida, M Hata, K Fujita, Y Ozawa, T Inoue

    RADIOLOGY   230 ( 1 )   93 - 99   2004.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1148/radiol.2301021143

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Retrospective comparison of clinical outcome between radiotherapy alone and surgery plus postoperative radiotherapy in the treatment of stages IB-IIB cervical squamous cell carcinoma. Reviewed

    Ohara K, Sugahara S, Kagei K, Hata M, Igaki H, Tokuuye K, Akine Y

    Radiation Medicine   22 ( 1 )   42 - 48   2004.1

     More details

  • FDG-PET scanning after radiation can predict tumor regrowth three months later Reviewed

    Koike, I, M Ohmura, M Hata, N Takahashi, T Oka, Ogino, I, J Lee, T Umezawa, K Kinbara, K Watai, Y Ozawa, T Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   57 ( 5 )   1231 - 1238   2003.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/S0360-3016(03)00757-0

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Intramedullary spinal cord germinoma: Case report and review of the literature Reviewed

    M Hata, Ogino, I, K Sakata, H Murata, N Kawano, S Matsubara

    RADIOLOGY   223 ( 2 )   379 - 383   2002.5

  • Radiation therapy for life- or function-threatening infant hemangioma. Reviewed

    Ogino I, Torikai K, Kobayasi S, Aida N, Hata M, Kigasawa H

    Radiology : an official journal of the Radiological Society of North America / RSNA   218 ( 3 )   834 - 839   2001.3

  • Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: Outcomes of late effects on pituitary function and growth in long-term survivors Reviewed

    M Hata, Ogino, I, N Aida, K Saito, M Omura, H Kigasawa, Y Toyoda, K Tachibana, S Matsubara, T Inoue

    INTERNATIONAL JOURNAL OF CANCER   96   117 - 124   2001

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ijc.10348

    Web of Science

    PubMed

    J-GLOBAL

    researchmap

  • Effects of irradiation on the sensitivity of melatonin release to norepinephrine in cultured pineal bodies of rats Reviewed

    K Saito, K Shinohara, M Morofushi, T Funabashi, D Mitsushima, M Hata, S Matsubara, F Kimura

    NEUROSCIENCE LETTERS   284 ( 1-2 )   93 - 96   2000.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/S0304-3940(00)00984-8

    Web of Science

    PubMed

    researchmap

▼display all

Books

  • 放射線治療計画ガイドライン 2020年版(分担執筆)

    幡多 政治

    金原出版  2020 

     More details

  • Proton Beam Therapy, Encyclopedia of Cancer, 4th Edition.

    Hata M

    Springer-Verlag Berlin Heidelberg  2017 

     More details

  • マイヤース腹部放射線診断学-発生学的・解剖学的アプローチ.

    太田 光泰, 幡多 政治

    2017 

     More details

  • Proton Beam Therapy, Encyclopedia of Cancer, 3rd Edition.

    Hata M

    Springer-Verlag Berlin Heidelberg  2011 

     More details

  • Proton Beam Therapy, Encyclopedia of Cancer, 2nd Edition.

    Hata M

    Springer-Verlag Berlin Heidelberg  2008 

     More details

MISC

  • 若年女性のホジキンリンパ腫に対して治療計画の工夫により被曝の低減を試みた一例

    西川雄太, 荻野伊知朗, 向井佑希, 間瀬美里, 石井好美, 幡多政治

    横浜医学   76 ( 1 )   5 - 10   2025.3

     More details

  • ここまで治る・ここまでわかった非黒色腫皮膚癌(NMSC) 非黒色腫皮膚癌に対する放射線療法

    幡多政治

    皮膚科   5 ( 6 )   591 - 596   2024.6

     More details

  • 肛門管扁平上皮癌に対する5-FUとMMCを用いた同時化学放射線療法の第II相試験. Editorial

    幡多政治

    JASTRO Newsletter   151   39   2024.3

     More details

  • 子宮頸がんの包括的戦略-ワクチン・検診・診断から最新治療まで- 進行子宮頸がんに対する放射線治療の進歩

    幡多政治

    産科と婦人科   90 ( 11 )   1251 - 1256   2023.11

     More details

  • 国内新規核医学治療 177Lu-DOTATATEの適応と治療の実際

    高野祥子, 小林規俊, 市川靖史, 幡多政治

    癌と化学療法   49 ( 8 )   813 - 820   2022.8

     More details

  • 177Lu標識ルテチウムオキソドトレオチドを用いたペプチド受容体核医学治療の空気中の放射能濃度

    高野祥子, 尾川松義, 小林規俊, 市川靖史, 細野 眞, 幡多政治

    Radioisotopes   71 ( 2 )   135 - 140   2022.7

     More details

  • 177Lu-PSMA核医学治療の現状と課題

    高野祥子, 上村博司, 幡多政治

    臨床泌尿器科   76 ( 8 )   772 - 779   2022.7

     More details

  • 放射線治療 神経内分泌腫瘍に対する核医学治療

    市川靖史, 小林規俊, 徳久元彦, 鈴木章浩, 大久保直紀, 田村繁樹, 竹田雄馬, 高野祥子, 宇都宮大輔, 幡多政治

    腫瘍内科   28 ( 5 )   498 - 504   2021.11

     More details

  • これからの核医学治療 ペプチド受容体放射性核種療法

    高野 祥子, 小林 規俊, 尾川 松義, 木藤 理恵, 山城 恒雄, 宇都宮 大輔, 市川 靖史, 幡多 政治

    核医学   58 ( Suppl. )   S103 - S103   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

    researchmap

  • ペプチド受容体放射性核種療法

    高野祥子, 小林規俊, 尾川松義, 木藤理恵, 山城恒雄, 宇都宮大輔, 市川靖史, 幡多政治

    核医学(Web)   58 ( Supplement )   2021

  • 18F-FDG-PET/CTを用いた食道癌N1リンパ節転移と放射線治療リンパ節領域範囲

    荻野伊知朗, 繁永大輔, 伊藤英子, 渡部成宣, 國崎主税, 幡多政治

    臨床放射線   65 ( 11 )   1207 - 1212   2020.10

     More details

  • 定番ブランドのフラッグシップ治療装置が大学病院の高度な放射線治療に求められる効率化、安定稼働、高精度照射を実現する

    幡多政治, 野村和人, 瀧下啓介

    月刊新医療   47 ( 8 )   8 - 13   2020.8

     More details

  • Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy

    Yuichiro Hayashi, Kohei Osawa, Rina Nakakaji, Shuhei Minamiyama, Nobuhide Ohashi, Takashi Ohya, Masaki Iida, Toshinori Iwai, Tomomichi Ozawa, Senri Oguri, Toshiyuki Koizumi, Makoto Hirota, Mitomu Kioi, Masaharu Hata, Kenji Mitsudo

    Head and Neck   41   1777 - 1784   2019.6

  • 鼻部に及ぶ進行上顎歯肉癌に対し4経路を用いた逆行性超選択的動注化学放射線療法により原発切除を回避できた1例

    小栗 千里, 光藤 健司, 大橋 伸英, 飯田 昌樹, 岩井 俊憲, 小泉 敏之, 廣田 誠, 來生 知, 海津 久, 幡多 政治, 藤内 祝

    横浜医学   69 ( 4 )   543 - 548   2018.10

  • 神経内分泌腫瘍のTheranostics ~Peptide Receptor Radionuclide Therapyの現状と今後の展望~

    高野 祥子, 小林 規俊, 金田 朋洋, 幡多 政治, 市川 靖史, 井上 登美夫

    臨床核医学   51 ( 3 )   38 - 42   2018.5

     More details

  • 骨髄線維症の脾腫に対する低線量脾照射 重篤な血球減少の回避

    幡多 政治, 石橋 直也, 小川 浩司, 赤松 芳行, 望月 隆男

    臨床放射線   63 ( 4 )   481 - 485   2018.4

  • 眼瞼癌の放射線治療 アイシールドによる視機能の温存

    幡多 政治, 金子 明博, 小池 泉, 海津 久, 向井 佑希, 高野 祥子, 伊藤 英子, 杉浦 円, 谷内 理紗, 水木 信久, 井上 登美夫

    臨床放射線   63 ( 3 )   329 - 335   2018.3

     More details

    Language:Japanese  

    DOI: 10.18888/rp.0000000372

    researchmap

  • Radio-Theranosicsの臨床展開-世界情勢と国内の現状-

    高野祥子, 小林規俊, 市川靖史, 上村博司, 中村元紀, 堀江慧一, 安田尚史, 伊藤賢一, 金田朋洋, 幡多政治

    核医学(Web)   55 ( Supplement )   2018

  • 頭部血管肉腫の放射線治療 X線と電子線による全頭皮照射

    幡多 政治

    臨床放射線   62 ( 13 )   1797 - 1804   2017.12

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

    DOI: 10.18888/rp.0000000211

    researchmap

  • Safety and Efficacy of Radiation Therapy for Very Elderly Patients Aged 80 Years or Older with Uterine Cervical Cancer

    M. Hata, I. Koike, E. Miyagi, R. Numazaki, M. Asai-Sato, H. Kaizu, Y. Mukai, S. Takano, E. Ito, M. Sugiura, T. Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   99 ( 2 )   E294 - E294   2017.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 前立腺癌に対する内分泌併用放射線治療後のテストステロン値に関する検討

    横溝 由美子, 上村 博司, 逢坂 公人, 蓮見 壽史, 林 成彦, 槙山 和秀, 近藤 慶一, 中井川 昇, 矢尾 正祐, 幡多 政治

    泌尿器外科   30 ( 臨増 )   929 - 929   2017.5

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    researchmap

  • 当院におけるハイリスク前立腺癌に対する内分泌療法併用IMRTの治療成績

    横溝 由美子, 上村 博司, 新堀 萌香, 荒木 あずみ, 逢坂 公人, 蓮見 壽史, 林 成彦, 槙山 和秀, 近藤 慶一, 中井川 昇, 矢尾 正祐, 糟谷 健夫, 幡多 政治

    日本泌尿器科学会総会   105回   PP19 - 06   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本泌尿器科学会総会事務局  

    researchmap

  • 放射線治療を理解するための基礎 放射線の基礎:核医学分野

    小池 泉, 幡多 政治, 井上 登美夫

    臨床泌尿器科   70 ( 9 )   650 - 654   2016.8

  • 最先端の放射線治療

    幡多 政治

    横浜医学   66 ( 4 )   577 - 588   2015.10

     More details

  • RADIATION THERAPY FOR PARA-AORTIC LYMPH NODE METASTASIS FROM UTERINE CERVICAL CANCER: OPTIMAL RADIATION DOSE ACCORDING TO METASTATIC LYMPH NODE SIZE

    M. Hata, E. Miyagi, I. Koike, R. Numazaki, M. Asai-Sato, T. Kasuya, H. Kaizu, Y. Mukai, E. Ito, M. Sugiura, M. Sato, F. Hirahara, T. Inoue

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER   25 ( 9 )   189 - 189   2015.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 前立腺癌に対する内分泌併用放射線療法後のテストステロン値に関する検討

    横溝 由美子, 上村 博司, 河原 崇司, 古屋 一裕, 泉 浩司, 逢坂 公人, 蓮見 壽史, 林 成彦, 槙山 和秀, 中井川 昇, 矢尾 正祐, 幡多 政治, 井上 登美男

    日本泌尿器科学会総会   103回   718 - 718   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本泌尿器科学会総会事務局  

    researchmap

  • Radiation Therapy for Primary Carcinoma of the Eyelid: Tumor Control and Visual Function

    M. Hata, I. Koike, J. Maegawa, A. Kaneko, K. Odagiri, T. Kasuya, Y. Minagawa, H. Kaizu, Y. Mukai, T. Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   84 ( 3 )   S513 - S513   2012.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 術前にホルモン療法を施行した密封小線源治療成績についての検討

    水野 伸彦, 上村 博司, 林 成彦, 蓼沼 智行, 中村 麻美, 佐野 太, 窪田 吉信, 小田切 一将, 皆川 由美子, 田山 芳史, 幡多 政治, 大村 素子, 井上 登美夫

    泌尿器外科   25 ( 8 )   1629 - 1632   2012.8

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    researchmap

  • 前立腺癌 ハイリスク早期癌の治療戦略 ハイリスク早期前立腺癌の治療戦略 IMRTを中心に

    林 成彦, 佐野 太, 三好 康秀, 上村 博司, 窪田 吉信, 皆川 由美子, 小田切 将一, 小池 泉, 幡多 政司, 荻野 伊知郎, 井上 登美男

    泌尿器外科   25 ( 臨増 )   963 - 964   2012.5

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    researchmap

  • Genitourinary toxicity after radiotherapy

    I. Koike, M. Hata, T. Inoue, M. Omura, H. Uemura, Y. Kubota

    Japanese Journal of Clinical Radiology   56   957 - 962   2011.8

     More details

  • 【高精度治療および短期照射治療に伴う有害事象】 放射線治療による排尿に関する有害事象 前立腺IMRT施行後2年までの排尿症状変化を中心に

    小池 泉, 幡多 政治, 大村 素子, 上村 博司, 窪田 吉信, 井上 登美夫

    臨床放射線   56 ( 8 )   957 - 962   2011.8

     More details

    Language:Japanese   Publisher:金原出版(株)  

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2011313157

  • The Role of Radiation Therapy for Stage IVB Uterine Cervical Cancer

    M. Hata, M. Omura, E. Miyagi, I. Koike, R. Numazaki, M. Asai-Sato, Y. Tayama, I. Ogino, F. Hirahara, T. Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   81 ( 2 )   S459 - S459   2011

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 当院における前立腺癌に対するIMRTの治療経過

    河原 崇司, 上村 博司, 幡多 政治, 関口 善吉, 南村 和宏, 伊藤 悠城, 佐野 太, 河路 かおる, 村上 貴之, 槙山 和秀, 中井川 昇, 小川 毅彦, 矢尾 正祐, 寺西 淳一, 皆川 由美子, 小田切 一将, 南澤 素子, 野口 和美, 井上 登美夫, 窪田 吉信

    泌尿器外科   23 ( 8 )   1165 - 1166   2010.8

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    researchmap

  • Endocrinopathies in Intracranial Germ Cell Tumor Patients Treated with Chemoradiation Therapy

    K. Odagiri, M. Omura, M. Hata, N. Aida, T. Niwa, S. Ito, H. Kigasawa, M. Adachi, T. Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   78 ( 3 )   S595 - S596   2010

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Prediction of Local Control in Head and Neck Cancer using the Maximal Standardized Uptake Value of Cu-62-ATSM

    Y. Minagawa, K. Shizukuishi, I. Koike, M. Hata, M. Omura, K. Odagiri, U. Tateishi, T. Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   78 ( 3 )   S435 - S436   2010

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Radiation Therapy for Primary Mucosa-associated Lymphoid Tissue (MALT) Lymphoma of the Orbit

    M. Hata, I. Ogino, M. Omura, I. Koike, S. Kurihara, Y. Tayama, K. Odagiri, Y. Minagawa, T. Inoue

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   75 ( 3 )   S484 - S484   2009

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 【癌克服の総合戦略 連携科学に基づく多角的アプローチ】 低侵襲かつ高精度を目指す局所療法 粒子線治療

    幡多 政治, 井上 登美夫

    カレントテラピー   26 ( 5 )   412 - 416   2008.5

     More details

    Language:Japanese   Publisher:(株)ライフメディコム  

    researchmap

  • 陽子線を用いた非共通面陽子線照射の実行可能性の検討

    水本斉志, 徳植公一, 林靖孝, 大川綾子, 福光延吉, 中山秀次, 幡多政治, 菅原信二, 大原潔, 秋根康之

    日本医学放射線学会学術集会抄録集   66th   S217   2007.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 肝門部に近接する肝細胞癌に対する陽子線治療の初期成績

    水本斉志, 徳植公一, 大川綾子, 林靖孝, 福光延吉, 幡多政治, 中山秀次, 菅原信二, 大原潔, 秋根康之

    日本医学放射線学会学術集会抄録集   66th   S216   2007.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Proton beam therapy for aged patients with hepatocellular carcinoma

    M. Hata, K. Tokuuye, S. Sugahara, E. Tohno, H. Nakayama, N. Fukumitsu, M. Abei, J. Shoda, M. Minami, Y. Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   69 ( 3 )   S305 - S305   2007

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 局所進行膵癌に対する陽子線照射方法の検討

    大川綾子, 徳植公一, 林靖孝, 水本斉志, 福光延吉, 中山秀次, 幡多政治, 菅原信二, 大原潔, 秋根康之

    日本放射線腫よう学会誌   18 ( Supplement 1 )   197   2006.10

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 頸癌腔内照射における子宮底部までへの線源留置は必須か

    大原潔, 水本斉志, 福光延吉, 幡多政治, 菅原信二, 徳植公一, 林靖孝, 大川綾子, 中山秀, 秋根康之

    日本放射線腫よう学会誌   18 ( Supplement 1 )   233   2006.10

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 髄膜腫に対する陽子線治療

    林靖孝, 徳植公一, 菅原信二, 幡多政治, 中山秀次, 福光延吉, 水本斉志, 大川綾子, 大原潔, 秋根康之

    日本放射線腫よう学会誌   18 ( Supplement 1 )   139   2006.10

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • I期の非小細胞肺癌に対する少分割陽子線治療の初期成績

    幡多政治, 徳植公一, 菅原信二, 影井兼司, 中山秀次, 福光延吉, 橋本孝之, 水本斉志, 大原潔, 秋根康之

    日本放射線腫よう学会誌   18 ( Supplement 1 )   162   2006.10

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Clinical results of proton beam therapy for locoregionally advanced esophageal cancer

    S. Sugahara, K. Tokuuye, A. Nakahara, M. Hata, H. Terashima, N. Fukumitsu, T. Shibahara, H. Nakayama, T. Hashimoto, K. Ohara, Y. Akine

    RADIOTHERAPY AND ONCOLOGY   81   S358 - S358   2006.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Conventional source dwelling up to the uterine fundus may not be mandatory in intracavitary radiotherapy for cervical cancer

    K. Ohara, K. Ohnishi, K. Nemoto, T. Hashimoto, N. Fukumitsu, M. Hata, S. Sugahara, K. Tokuuye, Y. Akine

    RADIOTHERAPY AND ONCOLOGY   81   S254 - S254   2006.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 【前立腺がん放射線療法の進歩】 EBRT+HDRbrachytherapy・重粒子線・陽子線の治療成績 限局性前立腺癌に対する陽子線治療

    宮永 直人, 赤座 英之, 及川 剛宏, 関戸 哲利, 樋之津 史郎, 河合 弘二, 島居 徹, 幡多 政治, 徳植 公一, 橋本 孝之, 福光 延吉, 菅原 信二, 秋根 康之

    泌尿器外科   19 ( 8 )   951 - 954   2006.8

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    researchmap

  • 子宮頚癌治療におけるネオアジュバント化学療法併用が放射線単独治療に比べ有効でなかった理由

    大原潔, 田中優美子, 大西かよ子, 根本景子, 橋本孝之, 福光延吉, 菅原信二, 幡多政治, 徳植公一, 秋根康之

    日本医学放射線学会学術集会抄録集   65th   S312   2006.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 消化管に近接した肝細胞癌に対する陽子線治療の初期成績

    徳植公一, 橋本孝之, 福光延吉, 幡多政治, 菅原信二, 根本景子, 大西かよ子, 大原潔, 秋根康之

    日本医学放射線学会学術集会抄録集   65th   S217   2006.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 合併症により治療法が制限された肝細胞癌患者に対する陽子線治療

    幡多政治, 徳植公一, 菅原信二, 福光延吉, 橋本孝之, 大西かよ子, 根本景子, 大原潔, 秋根康之

    日本医学放射線学会学術集会抄録集   65th   S315   2006.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 【消化器がんに対する放射線治療】 消化器がんに対する陽子線治療

    秋根 康之, 徳植 公一, 菅原 信二, 幡多 政治, 福光 延吉, 橋本 孝之

    臨床消化器内科   21 ( 3 )   315 - 322   2006.2

     More details

    Language:Japanese   Publisher:(株)日本メディカルセンター  

    researchmap

  • Preliminary results of hypofractionated proton beam therapy for hepatocellular carcinoma

    N. Fukumitsu, K. Tokuuye, T. Hashimoto, S. Sugahara, M. Hata, K. Ohara, E. Tohno, Y. Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   66 ( 3 )   S279 - S280   2006

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Repeated proton beam therapy for previously irradiated hepatocellular carcinoma - Dose-volume histogram (DVH) analysis

    T. Hashimoto, K. Tokuuye, K. Ohnishi, N. Fukumitsu, M. Hata, S. Sugahara, K. Ohara, E. Tohno, T. Nishimura, Y. Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   66 ( 3 )   S303 - S303   2006

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 陽子線治療により視神経が温存された横紋筋肉腫の1例

    根本景子, 菅原信二, 徳植公一, 奥村敏之, 影井兼司, 幡多政治, 井垣浩, 大原潔, 橋本孝之, 福光延吉, 秋根康之

    茨城県臨床医学雑誌   ( 41 )   33   2005.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 重症肝硬変症をともなう肝細胞癌患者に対する陽子線治療

    幡多政治, 徳植公一, 菅原信二, 影井兼司, 福光延吉, 橋本孝之, 大西かよ子, 根本景子, 大原潔, 秋根康之

    日本放射線腫よう学会誌   17 ( Supplement 1 )   106   2005.10

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 門脈腫よう栓を伴う肝細胞癌に対する陽子線治療の初期成績

    大西かよ子, 幡多政治, 徳植公一, 根本景子, 橋本孝之, 福光延吉, 影井兼司, 菅原信二, 大原潔, 秋根康之

    日本放射線腫よう学会誌   17 ( Supplement 1 )   89   2005.10

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • ペースメーカー装着患者に対する陽子線治療経験

    橋本孝之, 野間美緒, 徳植公一, 福光延吉, 幡多政治, 影井兼司, 菅原信二, 大原潔, 榊原謙, 秋根康之

    日本放射線腫よう学会誌   17 ( Supplement 1 )   168   2005.10

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis

    M. Hata, K. Tokuuye, S. Sugahara, K. Kagei, N. Fukumitsu, T. Hashimoto, K. Ohnishi, K. Ohara, Y. Matsuzaki, Y. Akine

    EJC SUPPLEMENTS   3 ( 2 )   224 - 225   2005.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Preliminary results of hypofractionated proton beam therapy for hepatocellular carcinoma

    N. Fukumitsu, K. Tokuuye, T. Hashimoto, S. Sugahara, K. Kagei, M. Hata, K. Ohara, Y. Akine

    EJC SUPPLEMENTS   3 ( 2 )   206 - 206   2005.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Preliminary results of proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

    K. Ohnishi, M. Hata, K. Tokuuye, K. Nemoto, T. Hashimoto, N. Fukumitsu, S. Sugahara, K. Ohara, Y. Matsuzaki, Y. Akine

    EJC SUPPLEMENTS   3 ( 2 )   223 - 223   2005.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 【前立腺癌治療の最近の進歩 とくに放射線療法】 前立腺癌に対する陽子線治療

    秋根 康之, 幡多 政治

    医学のあゆみ   212 ( 12 )   1063 - 1067   2005.3

     More details

    Language:Japanese   Publisher:医歯薬出版(株)  

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2005126740

  • 肝細胞癌に対する陽子線単独治療の治療成績

    徳植公一, 橋本孝之, 井垣浩, 幡多政治, 影井兼司, 菅原信二, 大城佳子, 福光延吉, 大原潔

    日本医学放射線学会学術集会抄録集   64th   S160   2005.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • <sup>99m</sup>Tc‐GSAによる肝腫よう陽子線治療後の肝予備能の経時的評価

    井垣浩, 徳植公一, 菅原信二, 影井兼司, 幡多政治, 武田徹, 福光延吉, 橋本孝之, 大原潔

    日本医学放射線学会学術集会抄録集   64th   S180   2005.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Repeated proton beam therapy for hepatocellular carcinoma

    T Hashimoto, K Tokuuye, K Nemoto, K Onishi, N Fukumitsu, H Igaki, M Hata, K Kagei, S Sugahara, K Ohara, Y Matsuzaki, Y Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   63 ( 2 )   S159 - S160   2005

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Clinical results of proton beam therapy for esophageal cancer at the University of Tsukuba

    S Sugahara, K Tokuuye, A Nakahara, H Igaki, M Hata, K Kagei, H Terashima, T Hashimoto, N Fukumitsu, T Shibahara, K Ohara, Y Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   63 ( 2 )   S163 - S164   2005

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 【前立腺がんの治療とケアの最前線】 前立腺がんに対する放射線療法

    幡多 政治

    看護技術   50 ( 14 )   1248 - 1252   2004.12

     More details

    Language:Japanese   Publisher:(株)メヂカルフレンド社  

    researchmap

  • 肝細胞癌の下大静脈腫瘍栓に対する陽子線治療

    水本 斉志, 徳植 公一, 橋本 孝之, 幡多 政治, 影井 兼司, 井垣 浩, 菅原 信二, 大原 潔, 秋根 康之

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   171 - 171   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • Clinical results of proton beam therapy for skull base chordoma

    H Iqaki, K Tokuuye, T Okumura, S Sugahara, K Kagei, M Hata, K Ohara, K Tsuboi, T Hashimoto, Y Akine

    RADIOTHERAPY AND ONCOLOGY   73   S258 - S258   2004.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Objective assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging

    K Ohara, S Sugahara, K Kagei, M Hata, H Igaki, T Hashimoto, K Tokuuye, Y Akine

    RADIOTHERAPY AND ONCOLOGY   73   S291 - S291   2004.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

    M Hata, K Tokuuye, K Ohara, S Sugahara, K Kagei, H Igaki, T Hashimoto, Y Matsuzaki, N Tanaka, Y Akine

    RADIOTHERAPY AND ONCOLOGY   73   S318 - S318   2004.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 門脈腫瘍栓をともなう肝細胞癌に対する陽子線治療

    幡多 政治, 徳植 公一, 菅原 信二, 影井 兼司, 井垣 浩, 橋本 孝之, 水本 斉志, 大原 潔, 秋根 康之

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   171 - 171   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 肝細胞癌の放射線治療計画における臨床標的体積の治療医間でのばらつきの検討

    橋本 孝之, 徳植 公一, 水本 斉志, 井垣 浩, 幡多 政治, 影井 兼司, 菅原 信二, 大原 潔, 秋根 康之

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   171 - 171   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 血清SCC抗原による子宮頸癌の放射線反応評価 MR画像による評価との比較

    大原 潔, 橋本 孝之, 影井 兼司, 幡多 政治, 井垣 浩, 菅原 信二, 水本 斉志, 徳植 公一, 秋根 康之

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   180 - 180   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 陽子線,重イオン線治療の基礎と展望

    幡多 政治

    呼吸   23 ( 10 )   772 - 777   2004.10

     More details

    Language:Japanese   Publisher:(一社)呼吸研究  

    researchmap

  • 肝細胞癌の陽子線治療における局所制御率の検討

    影井 兼司, 徳植 公一, 菅原 信二, 幡多 政治, 井垣 浩, 橋本 孝幸, 水本 斉志, 大原 潔, 秋根 康之

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   94 - 94   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 神経膠腫に対する陽子線治療成績

    井垣 浩, 徳植 公一, 坪井 康次, 菅原 信二, 影井 兼司, 幡多 政治, 橋本 孝之, 大原 潔, 秋根 康之

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   128 - 128   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 肝細胞癌に対する陽子線治療後の早期死亡(Early Death after proton beam therapy for hepatocellular carcinoma)

    大城 佳子, 井垣 浩, 徳植 公一, 幡多 政治, 影井 兼司, 菅原 信二, 大原 潔, 秋根 康之

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   130 - 130   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 巨大肝細胞癌に対する陽子線治療

    根本 景子, 徳植 公一, 大西 かよ子, 水本 斎志, 橋本 孝之, 井垣 浩, 幡多 政治, 影井 兼司, 菅原 信二, 大原 潔, 秋根 康之

    日本放射線腫瘍学会誌   16 ( 3 )   177 - 182   2004.9

  • 筑波大学陽子線医学研究利用センターにおける新陽子線施設での初期臨床経験

    影井 兼司, 徳植 公一, 菅原 信二, 幡多 政治, 井垣 浩, 橋本 孝之, 大原 潔, 秋根 康之

    日本医学放射線学会雑誌   64 ( 4 )   225 - 230   2004.5

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    researchmap

  • 子宮頸癌の縮小速度の比較 化学放射線治療vs放射線単独治療

    大原 潔, 田中 優美子, 大西 かよ子, 菅原 信二, 影井 兼司, 幡多 政治, 井垣 浩, 徳植 公一, 斎田 幸久, 秋根 康之

    日本医学放射線学会雑誌   64 ( 2 )   S214 - S214   2004.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    researchmap

  • Accuracy of respiratory-gated proton irradiation for liver tumor

    K Kagei, K Tokuuye, S Sugahara, M Hata, H Igaki, Y Tsunashima, T Sakae, K Ohara, Y Akine

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   60 ( 1 )   S428 - S428   2004

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 筑波大学陽子線医学利用研究センターにおける陽子線治療の臨床試験報告

    徳植 公一, 秋根 康之, 塩山 善之, 影井 兼司, 菅原 信二, 井垣 浩, 幡多 政治, 大原 潔, 橋本 孝之

    日本放射線腫瘍学会誌   15 ( 4 )   277 - 283   2003.12

     More details

    Language:Japanese   Publisher:(一社)日本放射線腫瘍学会  

    DOI: 10.11182/jastro1989.15.277

    researchmap

  • 【手術に代わる放射線治療】 浸潤性膀胱癌に対する膀胱温存療法

    幡多 政治

    映像情報Medical   35 ( 13 )   1090 - 1095   2003.11

     More details

    Language:Japanese   Publisher:産業開発機構(株)  

    researchmap

  • 肝細胞癌に対する陽子線治療における肝動脈塞栓療法の有無による治療成績の比較

    徳植 公一, 秋根 康之, 菅原 信二, 影井 兼司, 幡多 政治, 井垣 浩, 大原 潔, 根本 景子, 大西 かよ子

    日本放射線腫瘍学会誌   15 ( Suppl.1 )   80 - 80   2003.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 頭蓋底脊索腫に対する陽子線治療成績

    井垣 浩, 奥村 敏之, 徳植 公一, 菅原 信二, 影井 兼司, 幡多 政治, 大原 潔, 坪井 康次, 秋根 康之

    日本放射線腫瘍学会誌   15 ( Suppl.1 )   88 - 88   2003.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 子宮頸癌の腫瘍縮小速度の解析 放射線治療単独例と化学療法併用例との比較

    大原 潔, 大西 かよ子, 影井 兼司, 菅原 信二, 根本 景子, 幡多 政治, 井垣 浩, 徳植 公一, 秋根 康之

    日本放射線腫瘍学会誌   15 ( Suppl.1 )   142 - 142   2003.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    researchmap

  • 子宮頸部扁平上皮癌に対する根治照射と術後照射との治療成績の比較

    大原 潔, 菅原 信二, 影井 兼司, 徳植 公一, 幡多 政治, 井垣 浩, 秋根 康之

    日本癌治療学会誌   38 ( 2 )   691 - 691   2003.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • Effect of iodine group contrast media on repair process for radiation damages.

    MATSUBARA NOBORU, TORIGOE SOICHIRO, KURIHARA HIROAKI, HATADA MASAHARU

    Innervision   13 ( 9 )   49   1998.8

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

▼display all

Presentations

  • Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus.

    Hata M

    The 23rd European Society for Therapeutic Radiology and Oncology (ESTRO), Amsterdam  2004.10 

     More details

  • Radiation-based cancer imaging and therapy. Current status of charged particle therapy with proton and heavy ion beams.

    Hata M

    The 5th Four Universities’ Joint Seminar, Tokyo  2008.4 

     More details

  • Curative treatment with radiation therapy for extramammary Paget’s disease.

    Hata M

    The 24th European Society for Therapeutic Radiology and Oncology (ESTRO), Göteborg  2008.9 

     More details

  • Radiation therapy for primary mucosa-associated lymphoid tissue (MALT) lymphoma of the orbit.

    Hata M

    The 51st Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Chicago  2009.11 

     More details

  • Treatment outcomes of radiation therapy for primary subglottic cancer.

    Hata M

    The 29th European Society for Therapeutic Radiology and Oncology (ESTRO), Barcelona  2010.9 

     More details

  • The role of radiation therapy for stage IVB uterine cervical cancer.

    Hata M

    The 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO), Miami  2011.10 

     More details

  • Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function.

    Hata M

    The 54th Annual Scientific Meeting of the American Society for Radiation Oncology (ASTRO), Boston  2012.10 

     More details

  • Radiation therapy for extramammary Paget’s disease: treatment outcomes and prognostic factors.

    Hata M

    The 55th Annual Scientific Meeting of the American Society for Radiation Oncology (ASTRO), Atlanta  2013.9 

     More details

  • Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis.

    Hata M

    The 13th European Cancer Conference (ECCO), Paris  2005.10 

     More details

  • Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis.

    Hata M

    The 43rd Particle Therapy Co-operative Group (PTCOG) meeting, Munich  2005.12 

     More details

  • Proton beam therapy for aged patients with hepatocellular carcinoma.

    Hata M

    The 49th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles  2007.10 

     More details

  • Radiation therapy for sebaceous carcinoma of the eyelid: tumor control and preservation of visual function. Head and Neck Cancer. Poster Viewing Q&A Session.

    Hata M

    The 60th Annual Scientific Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio  2018.10 

     More details

  • The role and optimal regimen of radiation therapy for patients with bone metastasis from uterine cervical cancer.

    Hata M

    The 21st European Gynaecological Oncology Congress of the European Society of Gynaecological Oncology (ESGO), Athens  2019.11 

     More details

  • Radiation therapy for pelvic lymph node metastasis from uterine cervical cancer.

    Hata M

    The 33rd European Society for Radiotherapy and Oncology (ESTRO), Vienna  2014.4 

     More details

  • Radiation therapy for para-aortic lymph node metastasis from uterine cervical cancer: optimal radiation dose according to metastatic lymph node size.

    Hata M

    European Society of Gynaecological Oncology (ESGO) 19th International Meeting, Nice  2015.10 

     More details

  • Radiation therapy for angiosarcoma of the scalp: total scalp irradiation with X-rays and electrons.

    Hata M

    The 35th European Society for Radiotherapy and Oncology (ESTRO), Turin  2016.4 

     More details

  • Safety and efficacy of radiation therapy for very elderly patients aged 80 years or older with uterine cervical cancer.

    Hata M

    The 59th Annual Scientific Meeting of the American Society for Radiation Oncology (ASTRO), San Diego  2017.9 

     More details

  • Proton therapy for invasive bladder cancer: Treatment results of a bladder-preserving therapy with x-ray irradiation and concurrent intra-arterial chemotherapy followed by proton irradiation boost.

    Hata M

    The 12th European Cancer Conference (ECCO), Copenhagen  2003.9 

     More details

▼display all

Awards

  • Global Peer Review Awards.

    2019.9   Publons.   Top Peer Reviewer 2019.

    Hata M

     More details

  • 優秀教育展示賞.

    2018.10   日本放射線腫瘍学会第31回学術大会.   眼瞼の脂腺癌に対する放射線治療:腫瘍の制御と視機能の温存.

    HATA Masaharu

     More details

  • Peer Review Awards 2018.

    2018.9   Publons.   The Top Peer Reviewers.

    Hata M

     More details

  • 注目演題.

    2017.11   日本放射線腫瘍学会第30回学術大会.   乳房外Paget病の放射線治療:治療成績と予後因子の解析.

    HATA Masaharu

     More details

  • Peer Review Awards 2017.

    2017.9   Publons.   The Top Peer Reviewers.

    Hata M

     More details

  • Top Reviewers Award.

    2017.7   American Society for Radiation Oncology (ASTRO).   The Outstanding Reviewer of the International Journal of Radiation Oncology, Biology, Physics. [Int J Radiation Oncol Biol Phys 2017;99(1):1-2]

    Hata M

     More details

  • ARRO Poster Award.

    2013.9   American Society for Radiation Oncology (ASTRO).   Radiation therapy for extramammary Paget’s disease: treatment outcomes and prognostic factors.

    Hata M

     More details

  • International Poster Award.

    2011.10   American Society for Radiation Oncology (ASTRO).   The role of radiation therapy for stage IVB uterine cervical cancer.

    Hata M

     More details

▼display all

Research Projects

  • 体幹部放射線治療の四次元アルゴリズム解析:呼吸性移動の評価とレベル別対処法の意義

    2025 - 2027

    文部科学省  科学研究費補助金 基盤研究(C) 

    HATA Masaharu

      More details

    Authorship:Principal investigator 

    researchmap

  • 悪性腫瘍に対するRI内用療法の現状と課題:普及に向けた取り組みと新規治療法に関する研究

    2023

    PDRファーマ  医学・薬学に関する研究活動への支援 

    幡多 政治

      More details

  • 悪性腫瘍に対するRI内用療法の現状と課題:普及に向けた取り組みと新規薬剤の開発に関する研究

    2022

    PDRファーマ  医学・薬学に関する研究活動への支援 

    HATA Masaharu

      More details

    Authorship:Principal investigator 

    researchmap

  • 合併症を伴うがん患者における至適治療法の解明と治療法の標準化、新規治療法の開発に関する研究

    2022

    第一三共  奨学寄付プログラム 

    HATA Masaharu

      More details

    Authorship:Principal investigator 

    researchmap

  • 放射線治療計画における撮像条件が標的描出に与える影響

    2022

    GEヘルスケアファーマ  奨学寄附プログラム 

    HATA Masaharu

      More details

    Authorship:Principal investigator 

    researchmap

  • Clinical use for calcium phosphate cement paste marker in breast cancer and prostate cancer

    Grant number:21K07570  2021.4 - 2024.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant amount:\4030000 ( Direct Cost: \3100000 、 Indirect Cost:\930000 )

    researchmap

  • AYA(Adolescent & Young Adult,思春期・若年成人)世代のがん治療における至適治療法の解明と治療法の標準化、新規治療法の開発に関する研究

    2021

    第一三共 奨学寄付プログラム 

    幡多 政治

      More details

    Authorship:Principal investigator 

    researchmap

  • Impact of imaging conditions on the target delineation in radiotherapy planning

    2021

    GE Healthcare Pharma Educational Grant 

    Hata M

      More details

    Authorship:Principal investigator 

    researchmap

  • 放射線治療計画における撮像条件が標的描出に与える影響

    2020

    GEヘルスケアファーマ  奨学寄附プログラム 

    HATA Masaharu

      More details

    Authorship:Principal investigator 

    researchmap

  • 難治性がんに対する治療戦略:集学的治療による至適治療法の解明と標準化、新規治療法の開発に関する研究

    2020

    第一三共  奨学寄付プログラム 

    HATA Masaharu

      More details

    Authorship:Principal investigator 

    researchmap

  • 高齢者のがん治療における至適治療法の解明と治療法の標準化、新規治療法の開発に関する研究

    2019

    第一三共  奨学寄付プログラム 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 希少がんに対する至適治療法の解明と治療法の標準化、新規治療法の開発に関する研究

    2018

    第一三共  奨学寄付プログラム 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Research of conservative breast cancer treatment using calcium phosphate cement paste marker

    Grant number:17K10487  2017.4 - 2023.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    researchmap

  • 体幹部放射線治療における呼吸性移動 -四次元アルゴリズム解析と治療法の標準化-

    2017 - 2019

    文部科学省  科学研究費補助金 基盤研究(C) 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Molecular biological mechanisms of uterine leiomyoma growth.

    Grant number:15K10724  2015.4 - 2018.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    SATO Mikiko, HIRAHARA Fumiki, MIYAGI Etsuko, SAKAKIBARA Hideya, NAGASHIMA Yoji, YAMANAKA Shoji, HATA Masaharu

      More details

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    We have previously implicated erythropoietin (EPO) production in promoting the growth of some leiomyomas. In this study, we proceeded to explore the mechanisms of EPO production in leiomyomas and the role of EPO in leiomyoma growth. Thus, the relationship between EPO mRNA expression and the mutation of MED 12 gene, the major gene reported to be deeply involved in tumorigenesis of leiomyomas, was assessed.
    Consequently, we found robust increase of EPO only in MED12 wild type leiomyomas. In addition, estrogen induced EPO mRNA expression in MED12 wild type leiomomas whereas hypoxia did not affect EPO expression with or without the estrogen treatment.
    Since EPO expression level was significantly correlated with the tumor size, our study proposed a noble phenotype and mechanisms of leiomyomas to grow large in response to estrogen.

    researchmap

  • 強度変調放射線治療(IMRT)の最適化プログラムの開発

    2013

    一般財団法人横浜総合医学振興財団  奨励研究助成 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Molecular biological mechanisms of tumor growth in uterine leiomyoma

    Grant number:24592524  2012.4 - 2015.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    SATO Mikiko, MIYAGI Yohei, HIRAHARA Fumiki, MIYAGI Etsuko, NAGASHIMA Yoji, YAMANAKA Shoji, HATA Masaharu

      More details

    Grant amount:\4940000 ( Direct Cost: \3800000 、 Indirect Cost:\1140000 )

    Some uterine leiomyoma stay small, while others may enlarge tremendously. Myomatous erythrocytosis syndrome is a rare complication of uterine leiomyoma caused by erythropoietin (EPO) that is produced by tumor cells. We hypothesize that EPO may act as a factor that stimulates the enlargement of leiomyomas and assessed the EPO expression in leiomyomas and investigated the effects of EPO on the tumor growth.
    The mean EPO mRNA expression in the leiomyoma was higher than the corresponding normal myometrium by Real-time RT-PCR. A positive correlation of leiomyoma size and EPO mRNA expression was shown, suggesting the involvement of EPO in leiomyoma growth. Blood vessel maturity was also significantly increased in EPO-producing leiomyomas. As conclusions, EPO is produced in most of conventional leiomyomas and supports a model where EPO accelerates tumor growth, possibly by inducing vessel maturity. Our study suggests one possible mechanism by which some uterine leiomyomas reach a large size.

    researchmap

  • 放射線治療における医療用金属の散乱効果に関する研究

    2011

    (財)横浜総合医学振興財団  奨励研究助成 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Quantification of cell-free DNA in the plasma during radiation therapy

    Grant number:20591499  2008 - 2010

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    OMURA Motoko, HATA Masaharu, KOIKE Izumi, INOUE Tomio, ICHIKAWA Yasushi, MITUSDOU Kenji, KANG Yun, CHENG Chao, NATSUHORI Masahiro

      More details

    Grant amount:\3640000 ( Direct Cost: \2800000 、 Indirect Cost:\840000 )

    Cell-free plasma DNA is elevated in cancer patients and decreases in response to effective treatments. Consequently, these DNA have potential as new tumor markers. We investigated whether the plasma DNA concentrations in tumor-bearing mice and cancer patients are altered during the course of radiation therapy. The cell-free tumor specific DNA levels in the plasma of those mice were significantly associated with the tumor volume after radiation. The total cell-free plasma DNA levels in cancer patients showed dynamic changes associated with the progression of radiation therapy and decreased at end of the treatment. Additional analysis will be required to elucidate the potential clinical utility of dynamic changes in cell-free plasma DNA during radiation therapy.

    researchmap

  • 体幹部放射線治療における標的の呼吸性移動に関する研究

    2008

    (財)横浜総合医学振興財団  奨励研究助成 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 放射線治療の照射位置精度向上に関する研究

    2007

    (財)横浜総合医学振興財団  奨励研究助成 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 中枢神経系悪性腫瘍に対する放射線治療の基礎的研究

    2004 - 2005

    文部科学省  科学研究費補助金 若手研究(B) 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • メラトニンを用いた放射線照射が腫瘍細胞のアポトーシスとフリーラジカルに与える影響

    2002 - 2003

    文部科学省  科学研究費補助金 若手研究(B) 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 時間生物学的放射線治療法の確立

    1999

    文部省  科学研究費補助金 萌芽的研究 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 放射線照射のグリア細胞機能への影響

    1997

    文部省  科学研究費補助金 萌芽的研究 

    HATA Masaharu

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • The Effet of lodine-Based Contrast Agent on the Process of Radiation-Induced Damage Repair

    Grant number:08671045  1996 - 1998

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    MATSUBARA Sho, HATA Masaharu, TORIGOE Soichiro

      More details

    Grant amount:\800000 ( Direct Cost: \800000 )

    We analysed chromosomal aberrations in the peripheral blood after administration of contrast agents and gamma ray irradiation. Increased dicentric or ring chromosome formation was observed when adding contrast agents (3SOmOsm/Kg H_2O) within 15 min after gamma ray irradiation. When adding 60 min after irradiation, however, the rate of chromosomal aberrations markedly decreased, probably beacuse the process of chromosomal repair had been completed.
    Regarding molecular biological analysis we examined the phosphorylation or protein level of SAPK/JNK and GADD45 using confluent HeLa cells. Ten Gy of gamma ray irradiation with contrast agents upregulated GADD45 protein, but caused little change in SAPK/ JNK phosphorylation or protein level.

    researchmap

▼display all